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screening benefits: an ongoing  debate
Context
How can it be that the debate on the benefits of screening is still continuing, given five 
decades of research. Has this not yielded sufficient evidence? Today, in the three conti-
nents of Europe, North-America and Oceania, large-scale breast cancer screening pro-
grammes have been in existence for at least two decades.1 The launch of these program-
mes was initiated by an enormous amount of evidence regarding breast cancer mortality 
reduction from randomised trials and observational studies coming from demonstration 
projects in Europe, Canada and the United States, see Table 1.1. Currently, researchers are 
still debating the value of screening in terms of the prevention of breast cancer death. For 
example, in 2010 Kalager and co-workers2 concluded in The New England Journal of Medi-
cine, that the benefit of screening is “modest” [quotes by Guido van Schoor]. In that same 
year Mc Pherson3 and Jørgensen et al.4 concluded in the British Medical Journal: “Whatever 
we believe about the science, there is no doubt that screening for breast cancer has only 
limited benefits” and “We believe it is time to question whether screening has delivered 
the promised effect on breast cancer mortality”. With these recent quotes claiming only 
minor benefits of screening on breast cancer mortality my thesis begins, even though 
mammographic screening has been practiced for more than 50 years.
The impact of early breast cancer detection on mortality
It all started in 1963. A randomised trial to assess the effect of screening was set up within 
the Health Insurance Plan (HIP) of greater New York. Their first results showed that in 
the group of 30 000 women invited for screening just 31 breast cancer deaths emerged 
compared to 52 in the equally large not-invited control group.5
Subsequently, a number of randomised trials and demonstration projects were initi-
ated in Europe and North America to verify these promising results of the HIP study. In 
the Netherlands, projects were started in 1975 in Utrecht and Nijmegen;6,7 their results 
evaluated by case-referent studies confirmed the positive HIP findings.8,9 
Before deciding on the implementation of service screening, i.e. mammographic 
screening offered as a public health policy on a routine basis to the population, it is good 
practice in health care to conduct cost-effectiveness analyses. In the Netherlands, this 
analysis was based on the results from Nijmegen, Utrecht, New York and Sweden, and 
performed with the MISCAN micro-simulation model.10 This model predicted that from 
the start of a screening programme the breast cancer mortality rates would decline; in the 
year 2010 there would be 700 fewer breast cancer deaths than the expected 4200 deaths 
if there had been no screening. 
Despite all these developments, around the year 2000 new critical appraisals of the 
randomised trials emerged from the Northern Cochrane Centre in Denmark.11,12 The 
authors of this overview argued that the screening trials had poor validity. Their renewed 
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screening benefits: an ongoing  debate
conclusion was “There is no reliable evidence that screening decreases breast cancer 
mortality” and “Screening for breast cancer with mammography is unjustified”. 
Later on, interpretation of trends in declining breast cancer mortality gave support 
to these claims that screening is irrelevant. For example, Autier et al.25 emphasised that 
trends in breast cancer mortality do not endorse a substantial role for screening, because 
breast cancer mortality is also declining in countries without a screening programme and 
in not-invited age groups. In a recent report from Norway, a seemingly disappointing 10% 
of the estimated breast cancer mortality reduction was attributed to screening, while the 
remainder of the mortality reduction was attributed to increased breast cancer awareness 
and improved treatments.2 However, this study’s average follow-up of 2.2 years is simply 
too short a period to correctly estimate a mortality reduction because of screening. On 
the basis of the diverging trends in mortality over time between screened and unscreened 
women, more adequate follow-up will show that early detection accounts for a greater 
proportion of the trend in reduced breast cancer mortality.26-27 In an ecological study from 
Denmark, the authors claimed that, after 10 years, screening had no effect on breast can-
cer mortality. Unfortunately, the authors did not distinguish between deaths that were attri-
buted to breast cancers diagnosed before screening was introduced and deaths in patients 
diagnosed after the initiation of screening, resulting in a seriously flawed causal inference. 
The impact of these studies claiming minor benefits seems to have gained extraordina-
rily high exposure when compared to the rich literature published showing that mammo-
graphy screening accounts for a considerably greater proportion of the trend in reduced 
breast cancer mortality.27 For example, Nyström et al.28 conducted long term follow-up of 
the Swedish trials and demonstrated the stability of the beneficial screening effect. In the 
Netherlands, clear reductions in breast cancer mortality were observed in the screening 
target population over time,29,30 see Figure 1.1. 
Figure 1.1  Breast cancer mortality in women aged 40 - 94 in the Netherlands in 1989, 1999 and 
2009 (source: Statistics Netherlands).
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Many trend studies are hampered because of the aggregate level of data analysis, as the 
uptake of screening varies across individuals and within regions, leading to possible 
misclassification of screening. The use of individual data connecting a woman’s cause of 
death with her screening history would be a better approach. Therefore, we, in this thesis, 
have used the case-referent design, allowing us to make these linkages with individual 
data from the long term service screening programme in Nijmegen. This enables us to 
effectively investigate the current impact of service screening on breast cancer mortality. 
We prefer the term case-referent study to case-control study in this context, because the 
uptake of screening in the case group of breast cancer death is referred to the probability 
of having been screened in the population from which the cases originate. 
Age limits and screening interval
Related to the debate on the benefits, is the public health debate on the age range of the 
target population invited for screening. Most programmes invite women aged between 
50 and 69. In some countries screening is offered from age 40 or 45, while there are also 
countries that give elderly women the opportunity to participate.31 Currently, the Dutch 
programme invites women aged 50 - 75 for screening every 2 years. In the United King-
dom, Sasieni and Cuzick32 pleaded in the Lancet, “the age at which women are first invited 
for screening should be lowered to 47 years.”  
Screening younger women
So far there is no consensus that screening is beneficial in women under age 50.33 But, 
there are strong indications that this is no longer true given current screening practice; in 
the last decades major advances have been made in the organisation and use of mammo-
graphic screening technique.34-36 
In addition to improved screening techniques, lessons from the HIP trial have taught 
us that any screening effect in women under age 50 cannot be observed with short term 
follow-up.37 Longer follow-up in this age group is needed to discern the diverging trends 
in breast cancer mortality between the invited and uninvited groups. After 16 years the 
HIP study showed an equal screening effect in women under and over age 50.38 Only 
recently, Hellquist et al.39 concluded, 16 years after the start of service screening in 
Sweden, that mammographic screening for women aged 40 to 49 years was effective for 
reducing breast cancer mortality.
Evidence from the other early trials and demonstration projects regarding the efficacy 
of screening in younger women have not been convincing.40,41 In Sweden, they produced 
conflicting results,14,17,19,23,41 but the combined effect of these trials suggested a prevention 
of breast cancer death under age 50.33 In Canada, screening this age group could not 
be associated with a mortality reduction.20 However, none of these trials were designed 
to look at the effect of screening from age 40 on breast cancer mortality. The only trial 
 15
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that was especially designed for that purpose, i.e. the UK age trial, showed a statistically 
non-significant 17% breast cancer mortality reduction in the invited arm.24 This effect 
is probably an underestimation of the real screening - mortality association, since 20% 
of the invited women did not actually get screened and another 10% did not receive the 
recommended number of screens. Nonetheless, the statistical non-significance of this 
result hampers a decision on lowering the starting age of screening. On the other hand, 
a meta-analysis of all trials showed a statistically significant 15% breast cancer mortality 
reduction in women invited for screening between age 40 and 49.42 
There is an urgent need for more evidence regarding the intended effects of screening 
exams in women under age 50, because there has been a dramatic increase in breast can-
cer incidence under age 50 in the Netherlands. The current numbers of newly diagnosed 
patients between age 45 and 49 are even higher than the occurrence measured in women 
aged 50 - 59 at the start of national screening programme two decades ago, see Figure 1.2. 
However, we know, based on the above mentioned experience with the HIP study, that 
long-term follow-up screening data is needed to observe a convincing mortality reduction 
in women under age 50. Data from long-running screening programmes are limited, yet 
available in Nijmegen, where the programme started inviting women aged 35 and older 
in 1975. We have used these data to estimate the effectiveness of screening in this age 
group.
Screening the elderly
The burden of breast cancer has not only risen in young women, this has also happened 
in women older than 75, see Figure 1.2. The sharp decline in incidence in the age group 
75 - 79 is due to earlier detection of cancer by screening, which would, in the absence of 
Figure 1.2  Breast cancer incidence in women aged 40 - 94 in the Netherlands in 1989, 1999  
and 2009 (source: Comprehensive Cancer Centre Netherlands).
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screening be discovered symptomatically in that age group. The incidence of breast can-
cer in the age group 80 - 94 was 332 per 100 000 women in 1989 and increased to 386 per 
100 000 women in 2009. The continuation of screening after age 75 has received far less 
attention than screening for women in their forties. However, this issue is gaining more 
attention because of the ageing population. 
Women over age 75 have not been included in the trials. In addition, other considera-
tions like biological age, health status, life expectancy and individual preferences should 
play a role in decisions regarding screening this age group.43 Observational and modelling 
studies have indicated that screening in healthy women may be beneficial up to at least 
age 85.44,45
The major argument against screening this age group is that these women have a 
shorter life expectancy and are more likely to have co-morbidities than younger women. 
Therefore, even if elderly women are diagnosed with breast cancer they might be expected 
to die of other causes.46,47 To refute this assumption, we have accurately examined the 
burden of breast cancer among women after age 75.
Screening interval
Keeping the increase in breast cancer incidence under age 50 and over age 75 in mind, the 
policy of screening invitation may have to be reconsidered at both ends of the age range. 
Based on knowledge of breast cancer growth rates, it is recommended to screen more 
frequently in women under age 50 and less often after age 75.48 Although it is generally 
assumed that breast cancer grows faster in younger women, studies on the relationship 
between age and breast cancer growth rate are sparse and have used broad age cate-
gories, i.e. at least 20 year age groups, to analyse their data.48-51 By using such broad 
age categories, any age-specific difference will be incorrectly enlarged.52 For example, a 
gradual decrease in breast cancer growth rate between age 40 and 70 will be skewed by 
the extremes as a consequence of analysing data in two age categories.
In order to prevent over-screening in women under 50 if screened annually, and 
 under-screening among women older than 75 if screened every 3 - 5 years, we have  
further explored the age-specific preclinical growth rate of breast cancer. We used the 
Nijmegen data, where large series of longitudinal screening mammograms are available 
(N = 34 628), from which we know that, in retrospect, a lesion can be seen in 50% of the 
previous mammograms.53 
Contribution to the debate
The above mentioned arguments form the basis of the research conducted in this thesis 
on current effectiveness, age-targets and screening interval. Our results should contri-
bute to decision-making related to optimising the effectiveness of breast cancer service 
screening. 
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Abstract
Background – Favourable outcomes of breast cancer screening trials in 
the 1970s and 1980s resulted in the launch of population based service 
screening programmes in many Western countries. We investigated whether 
improvements in mammography and treatment modalities have had an 
influence on the effectiveness of breast cancer screening from 1975 to 2008.
Methods – In Nijmegen, the Netherlands, 55 529 women received an invi-
tation for screening between 1975 and 2008. We designed a case-referent 
study to evaluate the impact of mammographic screening on breast cancer 
mortality over time from 1975 to 2008. A total number of 282 breast can-
cer deaths were identified, and 1410 referents aged 50 - 69 were sampled 
from the population invited for screening. We estimated the effectiveness 
by calculating the odds ratio (OR) indicating the breast cancer death rate for 
screened versus unscreened women.
Results – The breast cancer death rate in the screened group over the com-
plete period was 35% lower than in the unscreened group (OR = 0.65; 95% 
CI = 0.49 - 0.87). Analysis by calendar year showed an increasing effective-
ness from a 28% reduction in breast cancer mortality in the period 1975 - 
1991 (OR = 0.72; 95% CI = 0.47 - 1.09) to 65% in the period 1992 - 2008 (OR 
= 0.35; 95% CI = 0.19 - 0.64).
Conclusion – Our results show an increasingly strong reduction in breast 
cancer mortality over time because of mammographic screening.
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Introduction
Breast cancer screening trials conducted in the 1970s and 1980s demonstrated a 20 - 
30% reduction in breast cancer mortality for women aged 50 - 69.1 On the basis of these 
trial results, service screening programmes for breast cancer were implemented on a 
large scale in Europe, North America and Australia in the 1990s.2 Subsequent evaluations 
of these programmes have shown a beneficial effect on breast cancer mortality, which has 
been comparable with the trial outcomes.3,4 
Since the trial era and the start of service screening, major advances have been made 
in the detection and treatment of breast cancer.5,6 The complete screening chain, from the 
technical aspects of mammography to the training and experience of radiographers and 
radiologists has improved. In addition, since the 1980s there has been a growing use of 
adjuvant therapy. No study has yet evaluated the influence of screening on breast cancer 
mortality taking into account the developments in screening performance and treatment 
over time.
Trends show a decline in breast cancer mortality. Some investigators have attributed 
this to screening and improved treatment,7-9 while others suggested that screening was 
not relevant.10-12 Although useful and important, the analysis of trends in breast cancer 
mortality should be interpreted with caution for inference on causal relations. Breast 
cancer mortality is also declining in age groups not invited for screening and in countries 
without a national screening programme.9
To achieve a reliable assessment of the effect of screening on mortality, it is necessary 
to make a direct link between a woman’s cause of death and her screening history.13 Data 
from long-running screening programmes are limited, except in Nijmegen, the Nether-
lands, where a programme for breast cancer service screening was started in 1975.14 
Between then and 2008, 405 131 invitations were sent to 55 529 women aged 35 years and 
older.
We have used data from this ongoing programme to investigate the impact of 
screening on breast cancer mortality between 1975 and 2008.
Materials and methods
The setting
We designed our study based on the population of women invited to the service screening 
programme in Nijmegen, the Netherlands. In 1975, this programme started inviting 
women aged 35 years and over for a biennial mammographic screening examination. In 
1989, at the start of the national screening programme, the age of invitation was gradually 
adapted to that of the national policy, which at that time was 50 - 69 years until 1997, and 
50 - 74 years from 1998 onwards. More than 257 300 screening examinations were perfor-
med up to 2008. The screening examination consisted of a two-view mammogram  
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(a mediolateral oblique and craniocaudal view) in initial screens. In subsequent 
screenings, the mediolateral oblique view is standard. Additional craniocaudal views 
are performed only on indication, for example, dense glandular tissue, implants and 
whenever abnormalities are suspected by the radiographer. At present, a craniocaudal 
view is conducted in about 50% of the women during subsequent examination. A detailed 
description of the programme has been published.15
A separate registry holds information on all patients with breast cancer in Nijmegen 
diagnosed within and outside the screening programme. Vital status was obtained from 
the Municipal Personal Records Data Base (GBA) up to and including 2008. Assessments 
of causes of death were made by a committee of physicians comprising a pathologist, 
medical oncologist and a radiologist. The committee members were unaware of the 
screening history. Both our screening and patient datasets are registered with the Nether-
lands Data Protection Authority.
Study design and study population
We applied a case-referent design13 to evaluate the effect of mammographic screening on 
breast cancer mortality by calendar year of invitation. Previous evaluations of screening 
have used the case-control design.4 We prefer the term case-referent study to case-control 
study in this context because the uptake of screening in the case group of breast cancer 
deaths is referred to the probability of having been screened in the population from which 
the cases originate. The lack of overlap in the age groups over calendar time prompted us 
to restrict the study population to women aged 50 - 69 at invitation.
In the case series of breast cancer deaths, we ascertained whether women were scree-
ned or not screened before breast cancer diagnosis, and calculated the odds of having 
been screened in this period. To interpret the screening odds in the case group, we also 
calculated the screening odds in a reference group. For each case, five referents were 
randomly sampled from the population of women invited for screening. Referents had 
to be eligible for screening, they did not have breast cancer at the time of invitation and 
were living in Nijmegen at the time of death of the case. This type of sampling follows 
the principle of incidence density sampling.16,17 The purpose of the case-referent design 
is to arrive at a valid estimate of the breast cancer mortality rate in both the screened and 
unscreened population.
Relevant time frame for screening
Screening can only be effective if the examination is performed in the period that breast 
cancer is developing and potentially detectable by the screening test before symptoms 
appear.18,19 The duration of the detectable preclinical period is unknown at the individual 
level; based on estimates of lead time for breast cancer18,19 we have set the time frame 
for screening invitation at a 4-year period before breast cancer diagnosis of the case. 
In a biennial screening schedule, this period includes two consecutive invitations, that 
is, the index-invitation (the most recent invitation before diagnosis of the case) and the 
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screening preceding the index. The year of index-invitation is the calendar year of the date 
of the invitation to the index-screening. The age at index-invitation is the age at this point 
in time. Both cases and referents have had the same opportunity for screening; therefore 
exposure to screening is defined as having been screened or not in the 4-year period.
As a result of this 4-year time frame and the constant participation in our programme, 
there are equal numbers of initial and subsequent screening examinations in our study 
population over time.
Analysis
To estimate the effect of screening on breast cancer mortality, we calculated the odds ratio 
(OR), using logistic regression techniques.20 The OR is the odds of having been screened 
versus not screened in the case series of breast cancer deaths, compared with the odds 
in the reference group from which the cases theoretically originate. As such, the OR is 
the breast cancer mortality in screened women divided by the breast cancer mortality in 
unscreened women.16 
First, the OR was calculated for the entire screening era from 1975 through 2008. 
Second, we calculated the ORs in the calendar periods 1975 - 1991 and 1992 - 2008. In 
order to make sure that the two groups were followed for an equal amount of time, we 
restricted this part of the analysis to cases who died within the same calendar period. 
Finally, the effect by calendar year (continuous variable) at index-invitation was assessed 
by including an interaction term, the combination of screening and calendar year, in the 
logistic regression model. We corrected the ORs for the confounding influence of age at 
index-invitation by stratification into 5-year age groups. SAS 9.2 software (SAS Institute 
Inc., Cary, NC, USA) was used for the analysis.
Results
Characteristics of the study population
Between 1975 and 2008, a total number of 282 breast cancer deaths were identified. We 
randomly sampled 1410 referents from the population invited for screening in the same 
period. The median age at index-invitation in the case group was 59 (interquartile range 
54 - 64) and 57 (interquartile range 53 - 62) in the reference group.
Screening effect
Over the entire screening period from 1975 to 2008, 191 cases were screened and 91 not 
screened, 1089 referents were screened and 321 not screened. After correction for the 
confounding influence of age at invitation, the screened women experienced a 35% lower 
breast cancer mortality rate compared with unscreened women (OR = 0.65; 95% CI = 
0.49 - 0.87; Table 2.1.1).
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Table 2.1.1  The effectiveness of mammographic screening on breast cancer mortality expressed by 
odds ratios, according to calendar period of index invitation and corrected for age at invitation.
Calendar period of  
index-invitation
Cases Referents Odds Ratio
(95% CI)
Screened
(unscreened)
Screened
(unscreened)
1975 - 2008 191 (91) 1089 (321) 0.65 (0.49 - 0.87)
1975 - 1991 90 (40) 501 (149) 0.72 (0.47 - 1.09)
1992 - 2008 29 (23) 202 (58) 0.35 (0.19 - 0.64)
Impact of calendar period
Among women invited between 1975 and 1991, screening prevented 28% of the other-
wise prevailing breast cancer mortality (OR = 0.72; 95% CI = 0.47 - 1.09; Table 2.1.1). In 
the period 1992 - 2008, the breast cancer mortality was 65% lower in screened women 
compared with unscreened women (OR = 0.35; 95% CI = 0.19 - 0.64); P-value for the 
interaction between period and screening effect = 0.04.
Detailed analysis of the influence of calendar year of invitation showed a trend of 
increasing effectiveness of breast cancer screening over time (1975 - 2008) (Figure 2.1.1); 
P-value for interaction = 0.02.
Discussion
The results of our study show an increase in impact of mammographic service screening 
on the prevention of breast cancer death over time. There are a number of possible expla-
Figure 2.1.1  The OR of breast cancer death for screened versus unscreened women invited in the 
period 1975 - 2008. The line represents the OR along the continuum of calendar year of screening 
invitation; the dotted lines represent the 95% confidence interval.
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nations for this increase in effectiveness. There have been significant improvements in 
mammographic screening and treatment over the last 30 years. However, methodological 
issues (confounding- and self-selection bias) may have influenced our results. We will 
discuss each of these points consecutively.
First, we believe that improvements in the quality of service screening,6,21,22 that is, pro-
gressions in quality assurance, training of radiographers and radiologists and advances 
in mammography techniques, have had an effect on the growing benefit of screening. The 
introduction of an anti-scatter grid for mammography, a radiation exposure dispenser, the 
daylight system and improvements towards smaller focal spots have led to higher image 
quality with less radiation exposure.6 
Second, multidisciplinary teams have been working on the assessment of recalled 
women and treatment of patients since the start of the screening programme.14 Improve-
ments in breast cancer treatment during the course of our study period have also resulted 
in a greater combined benefit of early detection and treatment. Since the 1970s, the use 
of chemotherapy and hormonal therapy after surgery has increased. In the Netherlands, 
this occurred predominantly between 1975 and 1990.23 A meta-analysis has shown that 
adjuvant treatment of early stage breast cancer reduces breast cancer mortality.5 This 
overview indicates that chemotherapy at an early stage of the disease reduced breast 
cancer mortality by 20% in women aged 50 - 69. Furthermore, in patients with oestrogen 
receptor positive breast cancer, chemotherapy followed by tamoxifen or the use of tam-
oxifen alone caused an even greater breast cancer mortality reduction: about 31%. The 
success of adjuvant treatment for early stage breast cancer emphasises the importance of 
the synergy between early detection and early treatment.24
Third, confounding bias could have had a role in our results, but we believe its 
influence on our effect estimates is marginal. The anticipated strong relation between a 
woman’s age and the occurrence of breast cancer death, and the age-related participation 
in our screening programme, prompted us to correct for age at invitation.
We considered to what extent residual confounding bias remains after having 
addressed the influence of age. One candidate may be mammographic density, which in 
itself is an important risk factor for breast cancer.25 However, the strong specific mammo-
graphic appearance composed of >75% of glandular tissue and stroma is only prevalent 
in about 5% of the post-menopausal women.26 A correction for age also implies an 
indirect correction for mammographic density, because of the high correlation between 
mammographic density and age.27
Other risk factors for breast cancer like obesity, socioeconomic status, nulliparity, 
late age at menopause, early age at menarche and family history show a 1.5 - 4-fold 
relative risk of breast cancer at most.28 Using sensitivity analysis29 we developed realistic 
scenarios of prevalence and strength of these risk factors on screened and not screened 
groups, and explored the impact of residual confounding bias. The results confirmed that 
a correction for residual confounding beyond age caused by these factors does not pro-
duce a major shift in our estimated OR.30 For instance, if a risk factor or risk profile with a 
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relative risk of four is present in 10% of the screened women compared with 20% in the 
unscreened women, then our apparent OR of 0.35 would be adjusted to 0.43. Our effect 
estimate will only weaken in an extreme situation where a combination of strong risk 
factors is much less present among screened women compared with unscreened women.
Finally, related to the issue of confounding, is bias because of self-selection. Mammo-
graphic screening may seem more effective than it in fact is if women who participate in 
screening programmes have a lower background risk of dying from breast cancer. In the 
literature, contradictory results have been noted with regard to the direction and magni-
tude of self-selection bias. Where Friedman and Dubin31 found that screened women were 
at higher baseline risk for breast cancer death, Moss32 found the opposite.
To obtain a fair estimate of the amount of self-selection, the ratio of the breast cancer 
death among not-invited women and non-participants has to be calculated.33 In our 
study, we were not able to calculate an estimate for self-selection, as we did not have an 
uninvited group for the main part of our study period. Nevertheless, we have two reasons 
for believing that the influence of self-selection bias in our results was only minor. First, 
during the early years, Verbeek et al.34 performed a geographical comparison on breast 
cancer incidence rates and found no evidence of self-selection bias. Second, recently we35 
quantified the extent of self-selection bias for a region close to Nijmegen. The resulting 
correction factor of 0.84 (95% CI = 0.58 - 1.21) indicates a lower background risk in 
women who do not attend screening. When we applied this factor to the formula descri-
bed by Duffy et al.33, our OR of 0.35 changed to 0.28. Since both studies showed no major 
influence of self-selection bias and because we had a constant participation rate in our 
programme, we expect no change in the amount of this bias over time.
In the literature many different estimates on the preventive effect of breast cancer 
screening have been published. It is important to consider that study design and method 
of analysis contribute greatly to these differences. More than two decades ago, trials were 
performed in a ‘laboratory’ setting, whereas cohort and case-referent designs are used 
to evaluate real-life current screening practice. In trials, non-compliance in the invitation 
arm, and contamination, that is, screening examination in the control (not invited) arm 
cause an underestimation of the actual screening effect.3 In cohort studies, differences in 
trends of breast cancer mortality are compared for screened and unscreened groups. A 
recent study on the Norwegian screening programme reported, after an average follow-up 
of 2.2 years, a seemingly disappointing 10% breast cancer mortality reduction because of 
screening.36 On the basis of the diverging trends in mortality over time, as was demon-
strated in a study from Sweden showing a 14% mortality reduction after 10 years in the 
age group 40 - 49,37 and a 29% reduction after 16 years,38 the Norwegian results can 
actually be regarded as very promising.
In comparison with cohort studies, the case-referent design does not allow for estima-
ting relative or absolute risks in breast cancer mortality. The advantage of the case-refe-
rent approach is that it directly links a woman’s cause of death with her screening history. 
Therefore, we can accurately estimate the OR of screened versus unscreened women in 
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the relevant time frame of screening invitation during the detectable preclinical period. 
As such, the OR is the mortality in screened versus not screened women. Case-referent 
studies from the England, Italy and Iceland, where screening started in the 1990s, showed 
a mortality reduction ranging from 41 to 65%.39-41 In general, the design used in these stu-
dies is similar to ours.42 The strength of our study is that we investigated temporal trends 
in screening effectiveness over time between 1975 and 2008.
In conclusion, we report on a strong and steady increase in the effectiveness of service 
screening on breast cancer mortality across the period 1975 - 2008, resulting in a 65% 
breast cancer mortality reduction in 1992 - 2008 compared with a 28% reduction in 
1975 - 1991. Our findings demonstrate that mammographic screening has become more 
effective over time.
34 
chapter 2
References
1 Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for 
breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 
2009;151:727-42.
2 Shapiro S, Coleman EA, Broeders MJM, Codd MB, de Koning HJ, Fracheboud J,  
Moss S, Paci E, Stachenko S, Ballard-Barbash R. Breast cancer screening programmes in 
22 countries: Current policies, administration and guidelines. Int J Epidemiol 1998; 
27:735-42.
3 Demissie K, Mills OF, Rhoads GG. Empirical comparison of the results of randomized  
controlled trials and case-control studies in evaluating the effectiveness of screening 
mammography. J Clin Epidemiol 1998;51:81-91.
4 Gabe R, Duffy SW. Evaluation of service screening mammography in practice: the impact 
on breast cancer mortality. Ann Oncol 2005;16 Suppl 2:153-62.
5 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy 
and hormonal therapy for early breast cancer on recurrence and 15-year survival: An 
overview of the randomised trials. Lancet 2005;365:1687-717.
6 Yaffe MJ, Mainprize JG, Jong RA. Technical developments in mammography. Health 
Phys 2008;95:599-611.
7 Levi F, Bosetti C, Lucchini F, Negri E, LaVecchia C. Monitoring the decrease in breast 
cancer mortality in Europe. Eur J Cancer Prev 2005;14:497-502.
8 Héry C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer inci-
dence and mortality since 1990 in 35 countries with Caucasian-majority populations. 
Ann Oncol 2008;19:1187-94.
9 Autier P, Boniol M, LaVecchia C, Vatten L, Gavin A, Héry C, Heanue M. Disparities in 
breast cancer mortality trends between 30 European countries: retrospective trend analy-
sis of WHO mortality database. BMJ 2010;341:c3620.
10 Zahl PH, Maehlen J. Reduction in mortality from breast cancer: decrease with screening 
was marked in younger age group. BMJ 2005;330:1024.
11 Becker N, Altenburg HP, Stegmaier C, Ziegler H. Report on trends of incidence (1970-
2002) of and mortality (1952-2002) from cancer in Germany. J Cancer Res Clin Oncol 
2007;133:23-35.
12 Jørgensen KJ, Zahl PH, Gøtzsche PC. Breast cancer mortality in organised mammogra-
phy screening in Denmark: comparative study. BMJ 2010;340:c1241.
13 Verbeek ALM, Broeders MJM. Evaluation of cancer service screening: case referent stud-
ies recommended. Stat Methods Med Res 2010;19:487-505.
14 Holland R, Rijken H, Hendriks JHCL. The Dutch population-based mammography 
screening: 30-year experience. Breast Care 2007;2:12-8.
15 Otten JDM, Van Dijck JAAM, Peer PG, Straatman H, Verbeek ALM, Mravunac M, Hen-
driks JH, Holland R. Long term breast cancer screening in Nijmegen, The Netherlands: 
the nine rounds from 1975-92. J Epidemiol Community Health 1996;50:353-8.
 35
2.1  increasing effectiveness of screening for breast cancer
16 Miettinen OS. Estimability and estimation in case-referent studies. Am J Epidemiol  
1976;103:226-35.
17 Greenland S, Thomas DC. On the need for the rare disease assumption in case-control 
studies. Am J Epidemiol 1982;116:547-53.
18 Weiss NS, McKnight B, Stevens NG. Approaches to the analysis of case-control studies of 
the efficacy of screening for cancer. Am J Epidemiol 1992;135:817-23.
19 Broeders MJM, Verbeek ALM. Mammographic screening only matters in the detectable  
preclinical period of breast cancer. J Med Screen 2005;12:107.
20 Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia: Wolters  
Kluwer Health/Lippincott Williams & Wilkins; 2008.
21 Hendrick RE, Klabunde C, Grivegnee A, Pou G, Ballard-Barbash R. Technical qual-
ity control practices in mammography screening programs in 22 countries. Int J Qual 
Health Care 2002;14:219-26.
22 Ichikawa LE, Barlow WE, Anderson ML, Taplin SH, Geller BM, Brenner RJ. Time  
trends in radiologists’ interpretive performance at screening mammography from the 
community-based Breast Cancer Surveillance Consortium, 1996-2004. Radiology 
2010;256:74-82.
23 Vervoort MM, Draisma G, Fracheboud J, van de Poll-Franse LV, de Koning HJ. Trends in 
the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect 
on mortality. Br J Cancer 2004;91:242-7.
24 Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Ya-
kovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality 
from breast cancer. N Engl J Med 2005;353:1784-92.
25 Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, 
Minkin S, Yaffe MJ. Mammographic density and the risk and detection of breast cancer. 
N Engl J Med 2007;356:227-36.
26 Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, Fajardo 
LL, Bassett L, D’Orsi C, Jong R, Rebner M. Diagnostic performance of digital versus film  
mammography for breast-cancer screening. N Engl J Med 2005;353:1773-83.
27 Groenwold RH, Nelson DB, Nichol KL, Hoes AW, Hak E. Sensitivity analyses to estimate 
the potential impact of unmeasured confounding in causal research. Int J Epidemiol 
2010;39:107-17.
28 Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast 
cancer: a review of risk assessment models. J Natl Cancer Inst 2010;102:680-91.
29 Schlesselman JJ. Assessing effects of confounding variables. Am J Epidemiol  
1978;108:3-8.
30 van Schoor G, Paap E, Broeders MJM, Verbeek ALM. Residual confounding after adjust-
ment for age: a minor issue in breast cancer screening effectiveness. Eur J Epidemiol 
2011;26:585-588.
31 Friedman DR, Dubin N. Case-control evaluation of breast cancer screening efficacy. Am J 
Epidemiol 1991;133:974-84.
36 
chapter 2
32 Moss SM. Case-control studies of screening. Int J Epidemiol 1991;20:1-6.
33 Duffy SW, Cuzick J, Tabár L, Vitak B, Chen THH, Yen MF, Smith RA. Correcting for 
non-compliance bias in case-control studies to evaluate cancer screening programmes. J 
R Statist Soc Ser C Appl Stat 2002;51 Part 2:235-43.
34 Verbeek ALM, Hendriks JHCL, Holland R, Mravunac M, Sturmans F, Day NE. Reduc-
tion of breast cancer mortality through mass screening with modern mammography. 
First results of the Nijmegen project, 1975-1981. Lancet 1984;1:1222-4.
35 Paap E, Holland R, den Heeten GJ, van Schoor G, Botterweck AA, Verbeek ALM, Broed-
ers MJM. A remarkable reduction of breast cancer deaths in screened versus unscreened 
women: a case-referent study. Cancer Causes Control 2010;21:1569-73.
36 Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on 
breast-cancer mortality in Norway. N Engl J Med 2010;363:1203-10.
37 Jonsson H, Tornberg S, Nyström L, Lenner P. Service screening with mammography in 
Sweden - evaluation of effects of screening on breast cancer mortality in age group 40-49 
years. Acta Oncol 2000;39:617-23.
38 Hellquist BN, Duffy SW, Abdsaleh S, Bjorneld L, Bordas P, Tabár L, Vitak B, Zackrisson 
S, Nyström L, Jonsson H. Effectiveness of population-based service screening with mam-
mography for women ages 40 to 49 years: Evaluation of the Swedish Mammography 
Screening in Young Women (SCRY) cohort. Cancer 2011;117:714-22.
39 Gabe R, Tryggvadottir L, Sigfusson BF, Olafsdottir GH, Sigurdsson K, Duffy SW. A case- 
control study to estimate the impact of the Icelandic population-based mammography 
screening program on breast cancer death. Acta Radiol 2007;48:948-55.
40 Allgood PC, Warwick J, Warren RM, Day NE, Duffy SW. A case-control study of the 
impact of the East Anglian breast screening programme on breast cancer mortality. Br J 
Cancer 2008;98:206-9.
41 Puliti D, Miccinesi G, Collina N, De Lisi, V, Federico M, Ferretti S, Finarelli AC, Foca F,  
Mangone L, Naldoni C, Petrella M, Ponti A, Segnan N, Sigona A, Zarcone M, Zorzi M, 
Zappa M, Paci E. Effectiveness of service screening: A case-control study to assess breast 
cancer mortality reduction. Br J Cancer 2008;99:423-7.
42 Paap E, Verbeek ALM, Puliti D, Paci E, Broeders MJM. Breast cancer screening case-
control study design: impact on breast cancer mortality. Ann Oncol 2011;22:863-9.


section 2.2
De-biasing the mortality 
effect estimates
Published in European Journal of Epidemiology 2011; 26: 585-588.
Residual confounding after adjustment for age: a minor issue in breast cancers screening 
 effectiveness.
G. van Schoor, E. Paap, M.J.M. Broeders, A.L.M. Verbeek.
40 
chapter 2
Abstract
Residual confounding, after adjustment for age, is the major criticism of 
observational studies on breast cancer screening effectiveness. We deve-
loped realistic scenarios for the prevalence and strength of risk factors on 
screened and not screened groups, and explored the impact of residual 
confounding bias. Our results demonstrate that residual confounding bias 
is a minor issue in screening programme evaluations.
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Introduction
Breast cancer screening programmes are now an established part of the health care ser-
vice of many countries.1 The continuous evaluation of this practice is based on observati-
onal studies, leading to the possibility of confounding and self-selection bias.
To assess the effect of screening, breast cancer mortality in both screened and not 
screened women has to be compared; this can be looked upon as the relative risk (RR, 
or rate ratio) of breast cancer mortality. Confounding bias of the RR occurs when the 
prevalence of a risk factor (or set of risk factors) for breast cancer death is imbalanced 
across the compared groups. To adjust for the confounding effect, the prevalence of the 
risk factor(s) has to become similar in both groups.
Usually age is the only risk factor measured when evaluating population-based breast 
cancer screening programmes, because information on date of birth and date of invita-
tion of women is mostly available. Therefore, after age, residual confounding bias in the 
screening - mortality relation remains the major criticism of observational studies. This 
term covers both within-stratum confounding, for example too-broad age categories, 
and confounding due to unmeasured variables.2 Self-selection bias can be regarded as a 
special form of residual confounding because participation may induce an imbalance in 
the risk factors for breast cancer death.
Having accounted for age, we clarified the influence of adjustment for residual con-
founding on the rate ratio of breast cancer death. We compared the mortality rate in the 
screened (Ms) with not screened women (Mns). This results in an ‘apparent’ screening 
- mortality association (RRa) that is seemingly real, but not necessarily so because of 
possible residual confounding bias. This effect of screening, RRa, can be unravelled in 
the ‘specific’ screening effect RRs, and a ‘non-specific’ effect of the potential confounding 
factor(s) C, which is reflected in the following formula.
RRa = Ms / Mns
 = RRs * C
 = RRs * [p1RRc + (1 – p1)] / [p2RRc + (1 – p2)]
The quantity C thus represents the effect of the potential confounder(s) among screened 
and the not screened women. The influence of C depends on the relative risk of breast 
cancer death RRc, the proportion p1 of screened women with the confounder present, and 
the proportion p2 of not screened women having the confounder. The formula is based on 
previous work by Cornfield and colleagues,3 Schlesselman4 and Greenland.5
 Suppose, as shown in Figure 2.2.1, that the apparent RRa is 0.50, and a risk factor 
producing a twofold increase in risk of breast cancer death (RRc) is present among 20% 
(p1) of the screened group and 50% (p2) of the not screened group. Then, the non-specific 
part of the apparent screening effect is 0.20 * 2 + 0.80 * 1 = 1.20 among the screened 
women, and 0.50 * 2 + 0.50 * 1 = 1.50 among the not screened women. The ratio of these 
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Figure 2.2.1  A heuristic device to address residual confounding in the mortality effect of breast 
cancer screening. 
Both arrows on the left indicate the observed breast cancer mortality risk in the screened and not 
screened group, suggesting RRa = 0.50. We assume that a confounder with a twofold relative risk on 
breast cancer death (RRc), is present among 20% (p1) of the women in the screened group and among 
50% (p2) in the not screened group. The arrow on the right indicates the expected breast cancer mortal-
ity risk in the not screened population when the presence of the risk factor in that group is adjusted from 
50% to 20%. The adjusted RRs becomes 0.63 (also demonstrated in Figure 2.2.2).
non-specific effects is 1.2 / 1.5 = 0.80, which is the influence of confounding (C) among 
the screened and not screened groups. Accordingly, the specific RRs will become 0.50 / 
0.80 = 0.63.
In the above calculation we used the cohort approach and the risk ratio (or rate ratio) 
as a measure of effect. However, this same method can be applied when the odds ratio 
(OR) is the effect measure. The case-control design has been increasingly used for the 
evaluation of screening programmes.6-12 In the case-control evaluation, the odds of having 
been screened versus not screened in the case group of breast cancer deaths is compared 
to the same odds in the control group of invited women from whom the cases originate. 
As such, the OR is the mortality in screened versus not screened women.
Example based on the Nijmegen Breast Cancer Screening Programme
As an example, we report on a case-control study conducted within the Nijmegen breast 
cancer screening programme which started in 1975. After adjustment for age, we found 
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that the breast cancer mortality rate in the screened group was 65% lower than that of the 
not screened group: OR = 0.35 and 95% confidence interval (CI) = 0.19 - 0.64.12 What role 
could residual confounding have played in this finding? 
Figure 2.2.2  Diagrams of the adjustment for residual confounding in the effectiveness 
 measurement of breast cancer service screening. 
Panel A shows the baseline situation of an age-adjusted screening - mortality OR = 0.35; panel B is for 
OR = 0.50 and panel C for OR = 0.75. From top to bottom, the figures represent the adjusted ORs for 
confounding factors with RRc = 6, 4, 2 and 1.5, respectively. The X-axis displays the proportion (p2) of 
the not screened population with the confounding factor. The lines displayed in the figures present the 
adjusted OR for the confounding factor for p2 ranging from 0.0 to 0.6, and four different points of depar-
ture for p1 of the screened population (upper line at p1 = 0.05, then p1 = 0.10, p1 = 0.20 and the lowest 
line p1 = 0.35). The Y-axis in each figure depicts the expected ORs adjusted for residual confounding.
Panel A: OR = 0.35
RRc = 6
OR = 
RRc = 4
RRc = 2
RRc = 1.5
X-axis: Among not screened women, proportion p2, with confounder
Panel B: OR = 0.5 Panel C: OR = 0.75
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Dense mammographic breast pattern, for which a high relative risk of 6 has been repor-
ted, is a likely candidate for being treated as a confounding factor.13 Despite its strength, 
this factor is not common in postmenopausal women. Nevertheless, suppose its preva-
lence in all screened women is 5% (p1 = 0.05) in contrast to a supposed 20% (p2 = 0.20) 
prevalence in the not screened women, then, according to the formula, the apparent OR 
of 0.35 would be adjusted to an OR of 0.56 (see also Figure 2.2.2, left upper diagram).
Other risk factors for breast cancer like obesity, socioeconomic status, nulliparity, 
late age at menopause, early age at menarche, and family history show a 1.5 to fourfold 
relative risk of breast cancer at most.14 We assume that the risk magnitude of the factors 
applies to the incidence and mortality alike. Figure 2.2.2 illustrates the impact these risk 
factors may have as confounders. Panel A shows the baseline situation of an age-adjusted 
screening - mortality OR of 0.35; Panel B is for OR = 0.50 and Panel C for OR = 0.75. The 
expected values of the ORs in order of decreasing magnitude are displayed on the Y-axis 
in each figure: after adjustment for dense breast pattern RRc = 6; late age at menopause 
RRc = 4; nulliparity RRc = 2; and serious overweight RRc = 1.5. The X-axis shows the pro-
portion (p2) of the not screened population with the confounding factor. In each figure, 
the lines present the OR adjusted for the confounding factor with p2 ranging from 0 to 
0.6, and four different situations of the proportion (p1) confounder in the screened group: 
the upper line is for a p1 = 0.05, then p1 = 0.10, p1 = 0.20 and the lowest line for a p1 = 
0.35. In practice, the deviations between apparent and adjusted ORs are minor.
Discussion
Previous screening programme evaluations have qualitatively discussed the magnitude of 
residual confounding bias on their effectiveness estimate6,9,10,12 or estimated the amount 
of bias due to self-selection.7,8,11 We present an educated and pragmatic method to 
quantify the potential impact of residual confounding, and to de-bias the comparison of 
screened with unscreened groups, a method originally introduced by Cornfield et al.3 Our 
results demonstrate that residual confounding has a minor influence on the observed 
screening effect.
Closely related to residual confounding is self-selection bias and healthy screenee 
bias. The difference between these three biases is subtle; the nuances seem to lie in the 
clarification of definable confounding factors or a combination of indefinable confoun-
ding factors. Self-selection into screening may result in an imbalance of a combination of 
indefinable risk factors, causing a different background risk of dying from breast cancer in 
screened versus not screened women.15 Healthy screenee bias may occur because some 
women in the not screened group, although invited for screening, may already have been 
diagnosed with cancer, while screened women were not diagnosed with breast cancer at 
the time of participation.16 Both biases can be regarded as a form of residual confoun-
ding17 since participation in screening may be correlated with the baseline risk of dying 
from breast cancer.
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An estimate of the amount of self-selection can be obtained by calculating the ratio of 
the breast cancer deaths among not invited and not screened women.18 This calculation 
is not possible in a steady state situation of population based screening since there is no 
uninvited group. By using the implementation period of screening, we11 quantified a 0.84 
lower background risk in not screened women compared with not yet invited women. A 
similar Italian study found a 1.11 higher risk in the not screened group.8 Duffy et al.18 pro-
posed a factor based on data from the Swedish and Canadian screening trials, showing a 
1.36 higher risk for not screened women. With these factors, the difference in background 
risk between not screened and screened women can be calculated by taking the percen-
tage uptake in a programme into account.18 For instance, if we use Duffy’s factor of 1.36 
and if the screening uptake is 80%, which is in accordance with most European program-
mes, not screened women have a 1.42 higher background risk compared with screened 
women. This factor actually represents C in our formula, it is the difference in background 
risk p1 = 0 and p2 = 1. In this scenario an apparent OR of 0.35 would be adjusted to 0.51. 
However, using our factor of 0.84, not screened women have a 0.80 lower background 
risk compared with screened women. In our scenario an apparent OR of 0.35 would be 
adjusted to 0.28.
In Cornfield’s original paper,3 he stated that a confounding factor completely explains 
an ‘apparent’ effect when the effect of confounding in the comparing groups equals the 
‘apparent’ effect, then RRa = C, and RRs = 1.
In our example we applied this method to adjust ORs for combinations of p2 between  
0 and 0.6, and values of p1 = 0.05, 0.10, 0.20 and 0.35. These values were chosen based 
on the expected prevalence of the risk factors in the female population, i.e. 5% for 
mammographic density, 10% for late age at menopause, 20% for nulliparity, and 35% 
for serious overweight. As, we aimed to challenge the age-adjusted screening effect, we 
developed scenarios where p1 was smaller than p2.
Our calculation does not account for random error or uncertainties about the relation 
of risk factors and breast cancer. It is possible to correct for this by using more complex 
techniques based on a Monte Carlo and a Bayesian approach.19 However, the aim of this 
study was to present a heuristic device to address residual confounding.
In conclusion, in studies on breast cancer screening the mortality reduction ranges 
from 38 to 70%.6-12 As we have shown, residual confounding does not have a great effect 
on these estimates of screening effectiveness. After having addressed for age, future 
breast cancer screening programme evaluations can ignore residual confounding.
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Abstract
Invasive lobular carcinoma (ILC) is the second most common type of 
breast cancer after invasive ductal carcinoma (IDC), accounting for 10% to 
15% of all invasive breast cancers. ILC is more difficult to detect by mam-
mography than IDC. Screening of the general population reduces breast 
cancer mortality by about 50%; to what extent is this true for ILC specifi-
cally? We designed a case-referent study to investigate the effect of mam-
mographic screening on ILC and IDC mortality using data from the Nij-
megen screening programme in the Netherlands, which started in 1975. 
Effectiveness was estimated by calculating the odds ratio (OR) indicating 
the breast cancer death rate in screened versus unscreened women. The 
effect of screening on death due to ILC was OR = 1.00 (95% confidence 
interval (CI) = 0.56 - 1.78). The OR for IDC was 0.63 (95% CI = 0.50 - 0.80). 
Our results show that screening does not help to prevent death in patients 
diagnosed with ILC. We discuss ways of improving screening in order to 
reduce deaths from ILC. 
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Introduction
Breast cancer is, histologically, a heterogeneous disease. Invasive ductal carcinoma (IDC) 
accounts for about 80% of all cases, and invasive lobular carcinoma (ILC) for 10 - 15% of 
all breast cancers.1 ILC tends to grow more diffusely than IDC. This behaviour hampers 
the ability of mammography to detect ILC at an early stage. As a result, ILC is more often 
detected as an interval cancer between two consecutive screens.2 It has been reported 
that false negative mammography rates are up to 19% higher in ILC compared with IDC.3 
Screening of the general population reduces breast cancer mortality by about 50%;4 
we were specifically interested in comparing the extent of mortality reduction in patients 
diagnosed with IDC and ILC. 
Methods
We designed a case-referent study within the population-based screening programme that 
started up in 1975 in Nijmegen, the Netherlands.5 The biennial screening examination 
consists of a two-view mammogram (a mediolateral oblique (MLO) and craniocaudal 
(CC) view) in initial screens. In subsequent screenings the MLO view is standard. Additi-
onal CC views are performed only on indication, for example in cases of dense glandular 
tissue, implants and whenever abnormalities are suspected by the radiographer.  
A detailed description of the programme has been published.6 
A separate registry holds information on all patients with breast cancer in Nijmegen 
diagnosed within and outside the screening programme. Vital status was obtained from 
the Municipal Personal Records Data Base (GBA) up to and including 2008. Assessments 
of causes of death were made by a committee of physicians comprising a pathologist, 
medical oncologist and a radiologist. The committee members were unaware of the 
screening history. Both our screening and patient datasets are registered with the Nether-
lands Data Protection Authority. 
Women who died from either ILC or IDC were selected as cases. In the case group 
we ascertained whether women were screened or not screened in a 4-year period prior 
to breast cancer diagnosis. We set this time frame for screening invitation based on 
estimates of lead time for breast cancer.7,8 In a biennial screening schedule, this period 
includes 2 consecutive invitations, i.e. the index-invitation (the most recent invitation 
prior to diagnosis of the case) and the screening preceding the index. Accordingly, the 
odds of having been screened in this period can be calculated. 
To interpret the screening odds in the case group, the same odds has to be calculated 
in a reference population. Therefore, for each case, we randomly sampled 5 referents from 
the population of women invited for screening. Referents had the same opportunity for 
screening as the corresponding case, did not have breast cancer at the time of invitation, 
and were living in Nijmegen at the time of death of the case. 
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Table 2.3.1  The effect of screening on ILC and IDC mortality expressed by odds ratio, after adjust-
ment for age.
Histology Cases Referents Odds Ratio (95% CI)
Screened 
(unscreened)
Screened 
(unscreened)
ILC 50 (20) 259 (91) 1.00 (0.56 - 1.78)
IDC 253 (158) 1553 (502) 0.63 (0.50 - 0.80)
We used logistic regression techniques to calculate the odds ratio (OR) of having been 
screened versus not screened in case series compared to the reference group from which 
the cases theoretically originate. As such, the OR is the breast cancer mortality in scree-
ned women divided by the breast cancer mortality in unscreened women.9 We calculated 
the OR for ILC mortality and IDC mortality separately. We corrected these ORs for the 
confounding influence of age at index-invitation by including age as a continuous variable 
in the logistic model. SAS 9.2 software (SAS Institute Inc., Cary, NC, USA) was used for 
the analysis.
Results
There were 70 ILC and 411 IDC cases in our study. The distribution of ILC and IDC cases 
did not change over time between 1975 and 2008. The OR for the effect of screening on 
ILC mortality was 1.00 (95% confidence interval (CI) = 0.56 - 1.78; Table 2.3.1). The OR 
calculated for the IDC group was 0.63 (95% CI = 0.50 - 0.80). 
Discussion
In this study we have demonstrated that there is no effect of screening on reduction of 
mortality in ILC patients; this compared to a significant mortality reduction in IDC. If 
detected at an early stage, ILC has a similar10,11 or possibly an even better prognosis than 
IDC.12 This may be due to a more favourable biological profile of ILC; these tumours are 
more likely to contain oestrogen receptor and progesterone receptor expressions, and 
normal expressions of Her2/Neu and p53.13 Therefore, it is a challenge for screening pro-
grammes to detect ILC at an early stage.
On the mammogram, in particular the MLO view, ILCs are usually difficult to identify. 
In the Dutch screening programme an MLO view is standard, whereas a CC view is only 
performed on indication. However, in most cases signs of ILC are better visible on a 
mammographic CC view.14
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Improvements in mammographic techniques may have resulted in an increased effec-
tiveness of screening on breast cancer mortality over time between 1975 and 2008. 
However, we do not expect this to be true for ILC mortality. We calculated an OR of 1 over 
the complete period, which would mean that, should there be an increasing effect on ILC 
mortality, the screening would have caused additional deaths in the early years, which is 
highly implausible. Due to the small numbers, we were not able to verify this assumption. 
Confounding bias could have played a role in our results, but we have strong indica-
tions that its potential influence on our effect estimates is marginal.15 The anticipated 
strong relation between a woman’s age and the occurrence of breast cancer death, and 
the age-related participation in our screening programme, prompted us to correct for age 
at invitation. Using sensitivity analysis we developed realistic scenarios for the prevalence 
and strength of other risk factors on screened and not screened groups, and explored the 
impact of residual confounding bias.15 These results demonstrated that residual confoun-
ding bias is a minor issue in screening programme evaluations.
Now digital mammography has recently been implemented in the Netherlands, it 
makes computer-aided detection relatively more easy to apply. In programmes that have 
applied this technique for some time, a promising mammographic sensitivity of more 
than 90% for detecting both ILC and IDC at an early stage have been reported.16,17
In conclusion, routine use of two-view digital mammography and computer-aided 
detection systems may, in the future, contribute to the reduction of breast cancer death 
from invasive lobular cancer. 
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3.1  screening performance along the continuum of age
Most countries which have implemented service screening on breast cancer invite women 
from age 50.1 With regard to younger women, findings from the UK age trial2 showed 
the same trend as previous studies3 that screening below age 50 has a positive effect on 
breast cancer mortality. For women screened at 40 - 49, Moss et al.2 reported a breast 
cancer mortality reduction of 17% at 10-year follow up (relative risk 0.83, 95% confidence 
interval 0.66 - 1.04). The statistical non-significance of these results hampers decisions 
on lowering the starting age of mammographic screening. On the other hand, these 
results also cast doubts on the validity of age 50 as the lower age limit for breast cancer 
screening. 
We evaluated (surrogate) impact indicators for mortality reduction, such as screen-
detected lymph node status, tumour size, and tumour stage; sensitivity of the mammo-
graphical screening test; mammographic density; and breast cancer occurrence along the 
continuum of age, to address the question whether breast screening should be extended 
to women under age 50. Our analysis thus addresses the matter of a gradual change with 
age in screening outcome measures instead of a sudden change, which seems to appear 
if data are analysed according to age dichotomised in <50 and ≥50.
Data were used from the Nijmegen breast cancer screening programme in the Nether-
lands.4 Tumour stage II or worse represents breast cancer with either tumour size ≤2 cm 
and lymph node positivity or tumour size >2 cm; stage I represents breast cancer with 
tumour size ≤2 cm and a negative lymph node status; and ductal carcinoma in situ was 
classified as stage 0. We calculated the rate of invasive disease with lymph node positive 
breast cancer, the rate of invasive disease with a diameter >2 cm, and the rate of tumour 
stage II or worse. The mammographic screening test sensitivity was calculated as the 
number of breast cancer detected through screening divided by the number of breast 
cancer detected through screening plus the number of interval cancers. Mammographic 
density was classified by a radiologist in one of two categories depending on the relative 
Figure 3.1.1  Proportion of women with mammographic dense breast patterns in Nijmegen,  
the Netherlands.
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amount of dense tissue: ≤25% was defined as lucent and >25% as dense.5 Dutch breast 
cancer incidence rates were calculated for two calendar years (1989 and 2003) with data 
from the National Cancer Registry and Statistics Netherlands.
We observed a gradual change with increasing age in screening outcome measures 
and breast cancer incidence (see Figures 3.1.1 and 3.1.2). This confirms the results from an 
earlier study by Kopans et al.6 that screening outcome measures do not change abruptly 
at age 50. Between 40 and 60 years, the detection rate of lymph node-positive disease 
remained roughly the same ~ 0.75 per 1000 screenees; the detection rate of tumour size 
>2 cm rose from 0.4 per 1000 women screened at age 45 to 0.5 per 1000 women scree-
ned at age 55; the detection rate of stage II or worse rose from 0.8 per 1000 screenees at 
age 45 to 0.9 per 1000 screenees at age 55; the mammographic screening test sensitivity 
rose from 42% at age 45 to 55% at age 55; the number of women with dense breasts gra-
dually declined from 50% at age 46 to 10% at age 60 (Figure 3.1.1); and the breast cancer 
incidence rates rose in 1989 and 2003 (Figure 3.1.2).
Breast cancer incidence rates in 2003 were higher compared with 1989, an increase 
which is not only limited to the age group eligible for screening but also between 45 and 
50 years of age. The breast cancer incidence rate at the start of the national mammograp-
hic screening programme, i.e. the incidence rate at age 50 in 1989 (228 per 100 000), 
now equals the rate at age 46 in 2003 (233 per 100 000). This increase may be explained 
by changes in risk factors for breast cancer related to endogenous hormones as stated by 
MacMahon,7 such as age at first birth, nulliparity, or onset of menses.
In conclusion, our analysis addresses the matter of a gradual change along the con-
tinuum of age in screening outcome measures and breast cancer incidence. The results 
indicate that the starting age of 50 years is to some extent arbitrary. Keeping the increase 
in breast cancer incidence below age 50 in mind, the starting age may have to be reconsi-
dered in favour of a younger age.
Figure 3.1.2  Breast cancer incidence in the Netherlands for 1989 and 2003  
(source: Comprehensive Cancer Centre Netherlands).
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Abstract
Background – The United Kingdom is currently moving the age limit for 
invitation in its national breast screening programme downwards from 50 
to 47. In contrast, the US Preventive Services Task Force concluded that, 
because of borderline statistical significance on effectiveness of mammo-
graphic screening, the current evidence is insufficient to advise screening 
in women aged 40 - 49.
Material and methods – We designed a case-referent study to investigate 
the effect of biennial mammographic screening on breast cancer mortality 
for women in their forties. In Nijmegen, the Netherlands, screening started 
in 1975. A total of 272 breast cancer deaths were identified, and 1360 refe-
rents aged 40 - 69 were sampled from the population invited for screening. 
Effectiveness was estimated by calculating the odds ratio (OR) indicating 
the breast cancer death rate in screened versus unscreened women. 
Results – In women aged 40 - 49, the effect of screening was OR = 0.50 
(95% confidence interval (CI) = 0.30 - 0.82). This result is similar to those 
aged 50 - 59 (OR = 0.54; 95% CI = 0.35 - 0.85) and 60 - 69 (OR = 0.65; 95% 
CI = 0.38 - 1.13). 
Conclusion – Our results add convincing evidence about the effectiveness 
of biennial mammographic screening in women aged 40 - 49.
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Introduction
In 2009, the US Preventive Services Task Force recommended against routine mam-
mographic screening in women aged 40 - 49. They concluded that current evidence is 
insufficient to advise screening under age 50, largely because of inconclusive statistical 
outcomes.1 In contrast to the United States, the United Kingdom is currently moving 
the age limit for invitation in the National Health Services Breast Screening Programme 
downwards from 50 to 47.2
Present discussions on screening under the age of 50 mostly concern annual 
screening and/or at least one exam additional to starting at age 50.3 We investigated the 
effectiveness of biennial mammographic screening by age, with a particular focus on 
women aged 40 - 49.
Material and methods
We designed our study based on the population of women invited to the screening pro-
gramme in Nijmegen, the Netherlands.4 In 1975, this programme started inviting women 
aged 35 years and over for a biennial mammographic screening examination. In 1990, at 
the start of the national screening programme, the age of invitation was adapted to that 
of the national policy (50 - 69 years until 1997 and 50 - 74 years thereafter). The lack of 
overlap in the age groups over calendar time prompted us to restrict the study population 
to women aged 40 - 69 at invitation between 1975 and 1990.
Our registry holds information on all patients with breast cancer in Nijmegen. Vital 
status was obtained from the Municipal Personal Records Data Base (GBA) up to and 
including 2008. Assessments of causes of death were made by a committee of physicians 
comprising a pathologist, medical oncologist and a radiologist.
We applied a case-referent design5 to evaluate the effect of mammographic screening 
on breast cancer mortality by age at invitation. Women who died from breast cancer and 
who were invited for screening between 1975 and 1990 were selected as case subjects. By 
means of incidence density sampling6,7 risk sets of referents were constructed, and from 
all sets five referents were randomly sampled for each case. Referents had to be eligible 
for screening, and living in Nijmegen at the time of death of the case.
Screening can only be effective if the examination is performed in the period when 
the cancer is potentially detectable before symptoms appear; the detectable preclinical 
period.8,9 The duration of the detectable preclinical period is unknown at the individual 
level; based on estimates of lead time for breast cancer,9,10 we have set the opportunity 
to screening for both the case and its referents at a 2-year period before diagnosis of the 
case. In a biennial screening programme this is the most recent invitation preceding the 
diagnosis, i.e. the index-invitation.8 Thus each case and its referents had been given the 
same index-invitation for screening; accordingly both cases and referents have had a simi-
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lar opportunity to participate in the screening examination following their index-invitation.
To estimate the effect of screening on breast cancer mortality, we calculated the odds 
ratio (OR), using logistic regression techniques. The OR is the odds of being screened 
versus not screened following the index-invitation in the case series of breast cancer 
deaths, compared with the reference group from which the cases theoretically originate. 
As such, the OR is the breast cancer mortality in screened women divided by the breast 
cancer mortality in unscreened women.6
We adjusted for differences in age at index-invitation between the comparison groups 
by stratification. Thereafter, we added the combination of screening and age as an inter-
action term to the logistic model to assess the effect of screening by age. Age was first 
added as 10-year age categories and after that as a continuous variable.
Results
We identified 272 cases, and we randomly sampled 1360 referents from the population invi-
ted for screening. The median age at index-invitation in the case group was 55 years (inter-
quartile range 49 - 62) and 49 years (interquartile range 44 - 54) in the reference group.
Women aged 40 - 49 at index-invitation had a 50% lower breast cancer mortality 
compared with unscreened women (OR = 0.50; 95% confidence interval (CI) = 0.30 - 
0.82; Table 3.2.1). Amongst women aged 50 - 59 and 60 - 69, screening prevented 46% 
(OR = 0.54; 95% CI 0.35 - 0.85) and 35% (OR = 0.65; 95% CI = 0.38 - 1.13) of the otherwise 
prevailing breast cancer deaths, respectively. The screening effect by age at invitation is 
displayed in Figure 3.2.1; p-value for the interaction term was 0.67.
Discussion
Our data demonstrate an effective biennial screening for women aged 40 - 49, which is 
similar to the screening effect in those aged 50 - 59 and 60 - 69. 
Table 3.2.1  The effectiveness of mammographic screening on breast cancer mortality expressed by 
odds ratios, according to age at index-invitation.
Age at index-invitation Cases Referents Odds Ratio (95% CI)
Screened
(unscreened)
Screened
(unscreened)
40 - 49 50 (26) 596 (154) 0.50 (0.30 - 0.82)
50 - 59 69 (39) 350 (107) 0.54 (0.35 - 0.85)
60 - 69 53 (35) 107 (46) 0.65 (0.38 - 1.13)
 69
3.2  starting screening at age 45
Evaluations from regions within Sweden and Canada, using a 12, 18 and 20 month 
screening interval, respectively,11-13 also found an effect of screening on breast cancer mor-
tality in women aged 40 - 49 that was similar to the effect in those aged above 50. These 
studies showed reductions in breast cancer mortality of 37 - 48% in women screened 
between age 40 and 49. Our findings indicate that a 2-year screening interval performs 
just as well as a shorter one.
The UK Age Trial,14 specifically designed to address the question of starting at age 40, 
showed after 10.7 years of follow-up a 17% breast cancer mortality reduction in women 
invited for screening (relative risk (RR) = 0.83; 95% CI = 0.66 - 1.04). The full effect of the 
UK Age Trial is not expected to have emerged yet, so a further follow-up is awaited.
Our results represent screening practice from 1975 to 1990. We believe that impro-
vements over time in mammographic detection techniques and treatment modalities 
are likely to result in an even greater beneficial effect on the prevention of breast cancer 
death. Since the start of screening programmes the complete chain, from technical 
aspects of mammography to training and experience of radiographers and radiologists 
has improved.15-17 In addition, since the 1980s there has been a growing use of adjuvant 
therapy.18
Declining trends in breast cancer mortality represent the advancements made in 
screening and treatment. Recently, Autier and colleagues19 reported that the strongest 
reduction is observed in women under age 50, usually not invited for screening. However, 
previous research has emphasised the importance of the synergy between early detection 
and treatment.20 The combination of screening and adjuvant treatment for early stage 
breast cancer in women under age 50 might therefore result in an even more substantial 
reduction in breast cancer mortality.
Figure 3.2.1  The odds ratio of breast cancer death in screened versus not screened women from 
40 to 69 years of age. The line represents the OR along the continuum of age at index-invitation; 
the dotted lines represent the 95% CI.
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The analysis of association in our study included participation of cases and referents 
following the index-invitation. An additional analysis including the invitation prior to the 
index-invitation, resulted in a small change in the mortality reduction, for instance the OR 
in women aged 40 - 49 changed from 0.50 to 0.57 (95% CI = 0.42 - 0.79). This indicates 
that a possible underestimation of the preclinical detectable period had no relevant 
impact in our study.
Confounding- and self-selection bias may have had an influence on our results. We will 
discuss these two biases consecutively. 
First, a notable candidate for producing confounding bias is mammographic density, 
i.e. the composition of glandular tissue and stroma, which is an important risk factor for 
breast cancer.21 By stratifying on age we indirectly corrected for mammographic den-
sity, because of the high correlation between age and mammographic density.22 Other 
risk factors for breast cancer like obesity, socio-economic group, nulliparity, late age at 
menopause, early age at menarche, and family history show a 1.5 - 4-fold relative risk of 
breast cancer at the most.23 Sensitivity analysis24 confirmed that, under realistic circum-
stances, a correction for residual confounding caused by these factors would not bring 
about a major shift in our estimated OR. For instance, if a risk factor or risk profile with 
a relative risk of 4 is present in 10% of the screened women compared to 20% in the 
unscreened women, then our apparent OR of 0.50 would be adjusted to 0.62. Our effect 
estimate will only weaken in an extreme situation where a combination of strong risk 
factors is much less present amongst screened women compared to unscreened women.
Second, mammographic screening may seem more efficacious than it in fact is if 
women who participate in screening programmes have a lower background risk of dying 
from breast cancer. To obtain a fair estimate of the amount of self-selection, the ratio 
of the breast cancer death rate amongst not-invited women and non-participants in the 
screening programme has to be calculated.25 In our study we were not able to calculate 
an estimate for self-selection, since we did not have an uninvited group for the main part 
of the study period. Nevertheless we have two reasons for believing that the influence of 
self-selection bias in our results was only minor. First, a geographical comparison, during 
the early years of the screening programme, on breast cancer incidence rates found no 
evidence of self-selection bias.26 Second, we27 recently quantified the extent of self-selec-
tion bias for a region close to Nijmegen. The resulting correction factor of 0.84 (95% CI 
= 0.58 - 1.21) indicates a lower background risk in women who do not attend screening. 
When we applied this factor to the formula described by Duffy and colleagues,25 our OR of 
0.50 changed to 0.40, which indicates a 60% reduction in breast cancer mortality.
The results of our study support lowering the starting age in breast cancer screening. 
A decision about the optimal age to commence screening should, however, also take into 
account cost effectiveness and the burden of breast cancer in younger women. In the 
Netherlands, the current breast cancer incidence at age 45 - 49 is similar to the incidence 
measured in women aged 50 - 59 at the start of the national screening programme two 
decades ago, whilst the incidence has only slightly increased in women aged 40 - 44.22 
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Breast cancer has thus become an important health problem in the age group 45 - 49. 
An additional economic evaluation is needed to underpin a possible decision to start 
screening at age 45.
In conclusion, our study adds convincing evidence on the effectiveness of biennial 
mammographic screening in women aged 40 - 49.
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Abstract
Women older than 75 are not invited for mammographic screening; if diag-
nosed with breast cancer, due to their anticipated short life expectancy, they 
are expected to die of other causes. To describe the breast cancer health 
problem in women older than 75, we estimated breast cancer incidence in 
this age group and the risk of breast cancer death in patients diagnosed 
after age 75 in Nijmegen, the Netherlands. Our findings demonstrate that 
in this age group, 3.3% of the women will be diagnosed with breast cancer, 
and that 1 in 3 of these incident cases die of this disease. These patients 
could have benefited from continued screening. 
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Introduction 
Women older than 75 are currently not invited to partake in the European breast cancer 
service programmes.1 The major argument against screening this age group is that these 
women have a short life expectancy and are more likely to have multi-morbidity compared 
with younger women. Therefore, even if elderly women are diagnosed with breast cancer 
they might be expected to die of other causes. Due to this potential risk of overdiagnosis, 
it is currently not deemed worthwhile inviting this age group for screening.2 
On the other hand, currently a large number of 75-year old women still have a favou-
rable life expectancy. A part of this group will be diagnosed with breast cancer and may 
ultimately die from this disease. These women could have benefited from screening.
Wilson and Jungner3 established a series of criteria that should ideally be fulfilled 
before considering screening as a public health policy. The decision to continue screening 
after age 75 should first be based on the question whether the disease is an important 
health problem.3 We therefore estimated longevity and the burden of breast cancer after 
age 75 in women who had been invited for screening up to that age.  
Methods
We designed our study within the population of women in Nijmegen, the Netherlands, 
who were invited for screening and reached the age of 75. A registry holds information on 
all patients with breast cancer in Nijmegen, through a link with the nationwide network 
and registry of histopathology and cytopathology (PALGA). Vital status was obtained from 
the Municipal Personal Records Data Base (GBA) up to and including 2008. Assessments 
of causes of death were made by a committee of physicians comprising a pathologist, 
medical oncologist and a radiologist. They were unaware of the screening history. Both 
our screening and patient datasets are registered with the Netherlands Data Protection 
Authority. Our registry does not contain data on co-morbidity.
We included all women who had been invited for screening and who had reached the 
age of 75 between 1975 and 2008. Data were collected on breast cancer occurrence, vital 
status and breast cancer death. 
We used Kaplan-Meier survival curves to estimate the life expectancy (median survival) 
starting from age 75. We censored on migration or end of study, i.e. 31 December 2008. In 
addition, we estimated breast cancer incidence for women aged 75 onwards. We calcula-
ted the risk of dying from breast cancer within 10 years following diagnosis using the 
Kaplan-Meier method. 
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Table 3.3.1  Longevity and the burden of breast cancer in women aged 75 and older.
Cohort 15 508 women aged 75 and older
Survival
    Lower quartile survival, years 5.6 (95% CI = 5.4 - 5.7)
    Median survival, years 10.0 (95% CI = 9.9 - 10.2)
    Upper quartile survival years 14.8 (95% CI = 14.6 - 15.0)
No. breast cancer (person years) 341 (103 374)
Breast cancer incidence 
per 100 000 person years
330    
    No. deceased 223
    No. died of breast cancer 73
    10 - year risk on breast cancer death 30.1% (95% CI = 24.1% - 37.2%)
Results
In total, 15 508 women matched our inclusion criteria. The median survival, starting at age 
75, among the women in this group was 10.0 years (95% confidence interval (CI) = 9.9 - 
10.2; Table 3.3.1); 25% of them lived less than 5.6 years (95% CI = 5.4 - 5.7), and another 
25% lived more than 14.8 years (95% CI = 14.6 - 15.0). 
In our study population, 341 women were diagnosed with breast cancer after rea-
ching the age of 75 (Table 3.3.1). The incidence rate of breast cancer was 330 per 100 000 
women years. Within 10 years after diagnosis, 223 patients had died, 73 due to breast can-
cer. Patients had a 30% risk of dying from breast cancer death within 10 years following 
diagnosis (95% CI = 24.1% - 37.2%). 
Discussion
The major argument against screening after age 75 is that these women have a shorter life 
expectancy and are more likely to have co-morbidities than younger women. Therefore, 
even if elderly women are diagnosed with breast cancer they might be expected to die 
from other causes. We show that in the group of women previously invited to screening, 
the incidence of breast cancer after age 75 is 330 per 100 000 women years. Given the 
median life expectancy of 10 years, approximately 3.3% of this population are likely to 
develop breast cancer between the age of 75 and 85. These incident patients sustain a 
30% risk of dying from this disease. Our findings emphasise the importance of the health 
problem caused by breast cancer in elderly women and the potential relevance of conti-
nued screening this age group.3 
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There is limited evidence for the effectiveness of screening the total female population 
after age 75; women in this age group were not included in the randomised screening 
trials. Data from the Swedish Two-County Trial showed a 32% (RR = 0.68; 95% CI = 0.51 - 
0.89) reduction in breast cancer mortality due to screening in the age group 65 - 74.4  
An evaluation from the Swedish service screening programme reported a 24% (RR = 0.76; 
95% CI = 0.57 - 1.19) breast cancer mortality reduction due to screening in women aged 
70 - 74.5 As far as we know, the only European study that examined the effect of service 
screening without an upper age limit showed a 44% (RR = 0.56; 95% CI =0.28 - 1.13) 
breast cancer mortality in women aged 65 and older who participate in screening.6 
However, screening does result in the diagnosis of earlier stage breast cancer,7 yielding 
the possibility of breast conservation treatment.8 This, in comparison with mastectomy, is 
associated with better quality of life.8 Therefore, we expect that early detection in com-
bination with less aggressive treatment may improve the quality of life of elderly breast 
cancer patients.
Compared to the level of the population, individual characteristics, such as multi-
morbidity or functional status, may strongly influence the likelihood of receiving benefit 
or harm from screening. Modelling studies have shown that screening may be beneficial 
up to at least age 85 in healthy women with life expectancies longer than 5 years.9 That is 
why the American Cancer Society10 has a preference for individualised screening rather 
than stopping at a certain age. This organisation suggests no upper age limit, but advises 
screening as long as the woman is healthy. In Europe screening is centrally organised with 
personal invitations up to age 70 or 75 on a population-based level.
In the United Kingdom, women can continue to be screened after reaching the upper 
age limit by requesting an individual screening examination (self-referral).11 We expect 
that in a system of self-referral to screening, healthy elderly women will actively choose to 
continue participating in screening and that these women may benefit from early breast 
cancer detection. 
A limitation of our study is that it describes a period of more than 30 years in which 
treatment of breast cancer has improved. This may have favourably influenced breast 
cancer survival over time between 1975 and 2008. On the other hand, breast cancer inci-
dence in elderly women has increased strongly in the Netherlands. For example, in 1989 
the incidence in the age group 80 - 94 was 332 per 100 000 women and this increased to 
386 per 100 000 women in 2009. Despite the possible improved survival of breast cancer 
patients, the rise in incidence indicates that nowadays breast cancer is still a health 
problem in elderly women. Due to limited data available we were not able to stratify our 
results with respect to calendar period of death. 
In conclusion, we report that 3.3% of the women aged 75 to 85 will be diagnosed with 
breast cancer, and that 1 in 3 of these incident cases will die from this disease. Our fin-
dings emphasise the importance of the health problem caused by breast cancer in elderly 
women.3 Our numbers alone do not justify an extension the upper limit of screening after 
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age 75. However, due to ageing of the European population, the contingent of healthy 
elderly women will further increase in the upcoming decades. If permitted, we expect that 
this group will actively choose to continue participating in screening. A solution for this 
age group would be to introduce and communicate11 a system where women can continue 
to be screened after reaching the upper age limit by requesting an individual screening 
examination.
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Abstract
Background – A meta-analysis of the randomised screening trials demon-
strated a 14% breast cancer mortality reduction in women aged 50 - 59 
and a 32% reduction in the age group 60 - 69. A possible explanation for 
this difference is the assumption that tumours among younger patients 
tend to grow faster than tumours among older patients. However, recent 
evaluations from service screening programmes covering a longer obser-
vation period have demonstrated similar effectiveness across the different 
age groups. This is not consistent with the prevailing view on age-specific 
tumour growth rate. We, therefore, studied the association between age 
and breast cancer growth. 
Methods – The analysis was conducted among 284 invasive ductal breast 
cancers diagnosed in women who had participated in the Nijmegen 
screening programme between 2000 and 2007. Longitudinal serial mam-
mograms were available for all these patients. We expressed growth rate 
by tumour volume doubling time (VDT) in days based on the assumption 
of exponential growth. The analysis was based on the increase in tumour 
diameter in time between at least two mammograms showing a measu-
rable tumour mass (n = 144), as well as on censored values calculated 
for cancers showing no growth (n = 21) and for cancers showing only one  
measurable tumour mass on the mammogram at diagnosis (n = 119). For 
this latter calculation, the mammographic density was taken into account. 
We applied regression analysis to assess the association between age and 
tumour volume doubling time.  
Results – The median age at diagnosis of the patients was 61 years (range 
51 - 87). The average VDT of the cancers was 236 days (95% CI = 213 - 258). 
For every year increase in age at diagnosis, the VDT increased with approxi-
mately one day although this was not statistically significant (b1 = 0.8 day; 
95% CI = -2.3 - 3.9). The VDT of interval cancers was 125 days faster than 
screen detected cancers (95% CI = 75.5 - 171.1). Adjustment for mode of 
detection did not influence the lack of association between age and VDT 
(b1= -0.1; 95% CI = -3.2 - 2.9). 
Conclusion – Our study shows that age and growth rate is not associated in 
ductal breast cancer patients aged 50 and 75 years. 
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Introduction
A recent meta-analysis of the randomised screening trials demonstrated a 14% breast 
cancer mortality reduction in women aged 50 - 59 and a 32% reduction in the age group 
60 - 69.1 The assumption that tumours in younger patients tend to grow faster than 
tumours in older patients,2 could be an important explanation for the smaller mortality 
reductions observed amongst women under age 60, compared to those over 60. 
Outcomes of modelling studies and evaluations of service screening programmes are 
not consistent in terms of age-specific screening effectiveness. The Cancer Intervention 
and Surveillance Modelling Network (CISNET) demonstrated, using six independent sta-
tistical models, that a biennial screening interval is the most efficient strategy to reduce 
breast cancer mortality for the ages 40 and 69.3 Based on these results, one would expect 
a constant growth rate of breast cancer along this continuum of age.
Data from the screening programme in Nijmegen, the Netherlands, initially showed 
age-specific differences in screening effectiveness.4 However, a longer follow-up of these 
data contradicted these findings.5 This inconsistency and the assumption that breast 
cancer at younger age grows faster than at an older age, prompted us to investigate the 
association between age at diagnosis and breast cancer growth rate.
Materials and methods
Source population
We designed our study based on the population of breast cancer patients who participa-
ted in the screening programme in Nijmegen, the Netherlands. In 1975, this programme 
started inviting women aged 35 years and over for a biennial mammographic screening 
examination. In 1989, at the start of the nationwide programme, the age of invitation was 
gradually adapted to that of the national policy, which at that time was 50 - 69 years until 
1997, and 50 - 74 years from 1998 onwards. The examination consists of a two-view mam-
mography (a mediolateral oblique and craniocaudal view) in initial screens. In subsequent 
screenings the mediolateral oblique view is standard. Additional craniocaudal views are 
performed on indication, for example, due to the presence of high percentage of dense 
glandular tissue, the presence of implants, or whenever abnormalities are suspected 
by the radiographer (at present about 50% of the women). A detailed description of the 
programme has been published.6 
The lack of overlap in the age groups over calendar time prompted us to restrict the 
data set to patients diagnosed between 2000 and 2007. During that time period, 636 
cancers were diagnosed in women who had participated in screening (Table 3.4.1). Of 
this group 440 patients had invasive ductal carcinoma, 88 invasive lobular carcinoma, 64 
ductal carcinoma in situ (DCIS), and the remaining 44 patients had another type of breast 
cancer. 
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Table 3.4.2  Observations used for analysing tumour volume doubling time. 
Mode of detection Not censored Left censored Right censored Drop outa Total
Screen detected 110 89 19 6 224
Interval 34 30 2 4 70
Total 144 119 21 10 294
a    Only visible on the diagnostic mammogram with a volume smaller than the assumed threshold  
volume; so no censored value could be calculated for the volume doubling time. 
Study population
We restricted the study population to the 440 patients diagnosed with invasive ductal 
carcinoma (Table 3.4.1). This type of breast cancer usually presents as a discrete mass 
on the mammogram,7 allowing for a direct measurement of tumour size. Invasive ductal 
carcinoma occurs in about 80% of all breast cancer patients,8 whereas this is expected to 
be 70% among the asymptomatic detected breast cancers. Invasive lobular carcinoma, 
the second most common type (10 - 15% of the patients), predominantly presents as an 
architectural distortion on the mammogram making it difficult to accurately measure the 
tumour diameter.7 DCIS generally presents as microcalcifications on the mammogram.
In our study population, 94 patients had no measurable tumour mass on the diagnos-
tic mammogram. These cancers were detected through microcalcifications (n = 30) or 
other indirect signs (n = 64), such as diffuse asymmetric density or nipple retraction. In 
52 of the 346 cancers with a measurable tumour mass on the mammogram at diagnosis, 
we could not trace the mammograms. 
Consequently, we selected 294 cancers for the analysis. Of this group, 10 patients had 
a tumour mass on the diagnosistic mammogram smaller than the threshold volume; so 
no censored value could be calculated for the VDT. The analysis of growth rate was based 
on the remaining 284 cancers with a measurable tumour mass on the mammogram at 
diagnosis (Table 3.4.2).
Two researchers measured the tumour mass on the diagnostic mammogram and the 
preceding screening mammogram, i.e. on the longest axis and at the right angle to the 
longest axis. For screen detected cancers, the preceding screening mammogram was the 
examination two years before detection. For cancers diagnosed in the interval between 
two consecutive screens, the preceding mammogram was the screening mammogram 
prior to diagnosis. The tumour mass was only measured on the mammographic mediola-
teral oblique view, because this view is standard procedure in subsequent examinations.9 
To assess the validity of our measurement we made a Bland-Altman plot10 by comparing 
our measurements of the diameter on the diagnostic mammogram with that described by 
the radiologist in the medical record. 
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To calculate the tumour volume (V) we used the formula for spheroids. 
 V = 4/3π * 1/2a * 1/2b * 1/2(1/2a + 1/2b),
where a, is the length and b, the width of the tumour mass. 
Calculation of growth rate and analysis
We expressed growth rate based on tumour volume doubling time (VDT) in days. First, 
volumes V1 and V2 were calculated, which stand for the tumour volume at diagnosis and 
at the screening examination, respectively. Assuming an exponential tumour growth, the 
VDT was estimated using the formula: 
VDT = (log 2 * t) / log (V1 / V2),
where t is the number of days between the diagnostic mammogram and the preceding 
screening mammogram. Volumes V1 and V2 were calculated in cubic centimetres.
If at least two mammograms with a measurable tumor nucleus shadow were available, 
the actual VDT could be estimated directly from the increase in tumour volume. If there 
was no observable growth, the VDT was certainly longer than the time interval between 
the two measurements, yielding a right-censored value for the actual tumour VDT.
In cancers in which a tumour mass could only be observed on the diagnostic mam-
mogram and not on the preceding screening mammogram, the size of the tumour mass 
at the time of the preceding mammogram was supposed to be too small to be visible 
radiographically. Visibility of tumours depends largely on mammographic density, i.e. the 
amount of glandular tissue and stroma.11 On a mammogram with low density, i.e. less 
than 26% of the breast tissue area, tumours with a diameter of approximately 5 mm in 
size could still be detected.2 This threshold of visibility increases on mammograms with 
greater density. Therefore, on mammograms with a density larger or equal to 26% we 
assumed that a tumour could be visible if it had a size of 10 mm. The classification of 
the mammographic density, based on the amount of glandular tissue and stroma, was 
derived from the medical record which was determined by the screening radiologist accor-
ding to the Wolfe classification.12
For cancers with a tumour mass only on the diagnostic mammogram, the actual VDT 
must be shorter than the VDT based on the above described threshold volume at the time 
of the preceding mammogram, yielding a left-censored value for the actual VDT. 
Statistical analysis
We used linear regression techniques13 to determine the association between age at 
diagnosis and VDT. Since screening with a 2-year interval is more likely to detect slo-
wer growing tumours than those that grow more rapidly (length time bias), and since 
tumours that occur at younger ages are expected to grow faster, we adjusted the associ-
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ation between age and VDT for the possible confounding influence of mode of detection 
(screen- or interval-detected). 
Results
Measurement of the tumour mass
Figure 3.4.1 displays the Bland-Altman plot10 for the agreement between our measurement 
of tumour diameter with that described by the radiologist in the medical record. The 
mean difference is 0.51 percent points with a 95% confidence interval (CI) of 0.07 to 0.95. 
Thus, we measured a slightly larger diameter of between 0.07 and 0.95 mm. As can be 
seen from the figure, this difference did not seem to be dependent on the mammographic 
size of the tumour.
The average tumour volume (V1) that we measured on the diagnostic mammogram 
was 3.74 cm3 (95% CI = 2.65 - 4.82). The average volume (V2) on the preceding mam-
mogram was 1.45 cm3 (95% CI = 0.69 - 2.21). The mean time between diagnostic and 
preceding screening mammogram was 689 days (95% CI = 673 - 704), that is 1.89 years 
(95% CI = 1.84 - 1.93).
Growth rate  
The mammogram series that we used to analyse tumour volume doubling time is shown 
in Table 3.4.2. The mean VDT was 236 days (95% CI = 213 - 258). Figure 3.4.2, displays the 
different values for VDT according to age at diagnosis. For every year increase in age at 
Figure 3.4.1  Bland-Altman plot showing the mean difference in tumour measured in this study 
and in the medical record, based on 284 patients used for analysing the VDT.
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diagnosis, the average VDT rose by 0.8 days (b1 = 0.8 day; 95% CI = -2.3 - 3.9; Table 3.4.3). 
The mean VDT was 226 days at age 50. Although statistically insignificant, the average 
VDT increased to 242 days at age 75. 
Screen detected cancer had an average VDT of 272 days (95% CI = 245 - 290) and 
interval cancers had a VDT of 147 days (95% CI = 114 - 180). After adjustment for mode  
of detection, b1 for the association between age at diagnosis and VDT was -0.1 day (95% 
CI = -3.2 - 2.9). 
Table 3.4.3  Relationship between age and tumour volume doubling time in days, taking into ac-
count mode of detection, using linear regression.  
Model 95% Confidence interval for the bi
Variable bi-coefficient Lower boundary Upper boundary
1 Intercept b0 = 186.1  -10.8  382.9
X1 b1 = 0.8  -2.3  3.9
2 Intercept b0 = 154.0  -35.7       343.7
X1 b1 = -0.1  -3.2         2.9
X2 b2 = 125.3  77.9  172.6        
X1 is age in years;                      with X1 = 50 if age is 50, X1 = 51 if age = 51, etc. 
X2 is mode of detection;            with X2 = 1 if screen detected cancer and X2 = 0 if interval cancer.
Figure 3.4.2  Tumour volume doubling time (VDT) according to age at diagnosis, based on 284 
breast cancer patients.
The regression line equation, plotted in this figure is as follows: Y = 186.1 + 0.8 * X1, where Y is the aver-
age VDT and X1 age in years. X1 = 50 if age is 50, X1 = 51 if age is 51, etc.
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Discussion
Our results suggest that age is not associated with growth rate of breast cancer as appa-
rent on serial mammograms of invasive ductal carcinoma patients aged 50 to 75. This 
means that when similar effectiveness across age groups is taken into account, screening 
is likely to discover an equal proportion of tumours along the continuum of age before 
their fatal diameter occurs.14 Theoretically, each tumour has a size at which the cancer 
becomes fatal, i.e. (micro) metastases have spread and the available treatment options 
are no longer curative. A patient can only be cured if the tumour is treated before it has 
reached this fatal diameter.    
Comparison with other studies
Previous empirical results on age and breast cancer growth rate have been scarce and 
most of these studies used series of clinical mammograms in patients. For example, in 
the 1970s, Kusama et al.15 found that doubling times less than 2 months were signifi-
cantly more frequent in patients younger than 60 when compared to older patients. Von 
Fournier et al.16 compared the VDT in women under age 50 with those aged over 70, and 
reported a VDT of 210 days and 244 days for these age groups respectively. Finally, in the 
1990s, Spratt et al.17 observed growth rates in a clinical data set of mammograms in 448 
breast cancer patients age 18 to 88. They determined differences of VDT between age 
groups by analysis of variance and found no relation between age and growth rate. The 
average VDT reported in Spratt’s study was 260 days. 
As far as we know the only study that has looked at age and breast cancer growth rate 
using serial screening mammograms was performed by Peer et al.2 This study analysed 
data from the early years of the Nijmegen screening programme. Peer et al.2 calculated 
a median VDT of 80 days in women younger than 50 years of age, a VDT of 157 days 
in women aged 50 - 69 years and a VDT of 188 days in women 70 years and older. The 
median VDT of 194 in our study is 37 days slower than that reported in Peer’s study for 
the age group 50 - 69. As reported in the results section of this manuscript, the average 
VDT in our dataset was 236 days, indicating the skewed distribution of our dataset. The 
difference in median VDT between both studies might be explained by a systematic error 
in measurements of the tumour sizes. However, both studies used a similar measuring 
technique. Therefore, improvement of the quality of mammograms over time might be an 
alternative explanation for the different study outcomes.18 
In addition, the age-specific differences in VDT reported in Peer’s study may be a con-
sequence of using broad age categories to analyse the data. By doing so, any age-specific 
difference will be artificially enlarged.19 For example, a gradual decrease in breast cancer 
growth rate between age 50 and 75 may be skewed by the extremes as a consequence of 
grouping the data.
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Limitations of our study
As in the above mentioned studies, we based our growth calculation on the exponential 
tumour growth model. However, the Gompertz function, where growth is exponential 
in the beginning and slows down at a later phase, is probably a more realistic model for 
tumour growth over time.20 Under influence of the available blood supply for the nucleus 
of the tumour, growth may slow down or perhaps temporarily fall in large tumours. We 
did not have enough longitudinal measurements to fit this function to our data; only 4 
patients had a tumour mass on 3 consecutive screening mammograms. However, we 
used data from the early preclinical stages of tumour development, where the Gompertz 
function approximates the exponential function.20 
Our measurement of the tumour mass may not have been precise in all tumours. On 
a large proportion of the mammograms the tumour border could not be exactly defined 
because of the high density of the surrounding tissue. An additional analysis, including 
mammographic density in the regression equation, resulted in a small change for our 
association between age and VDT, i.e. b1 changed from 0.8 to 1.1 days. It not likely that a 
systematic measurement error of the diameters of tumour mass in serial mammograms 
affected our association between age and VDT.
We restricted the analysis to patients with invasive ductal carcinoma. The proportion 
of invasive ductal carcinoma, invasive lobular carcinoma and DCIS are more or less simi-
larly distributed over the ages.8 This, together with the observation that invasive ductal 
carcinoma occurs in about 80% of the patients, leads us to expect that the restriction of 
our study population had no consequence for our conclusion on age and breast cancer 
growth rate.
Unanswered questions
Unfortunately, we had no data on patients younger than age 50. It is hypothesised that 
the biology of breast cancer is age-dependent and that this has to do with the patients 
menopausal status during onset of breast cancer.21 Early onset breast cancers diagnosed 
in premenopausal women are assumed to be faster growing compared with late onset 
breast cancers diagnosed among post-menopausal women.21,22 Although menopause 
occurs on average at age 50, there is great variability among individual women.23 Thus, 
it seems more realistic that menopausal changes happen gradually between age 45 
and 55.24,25 Therefore, we do not expect alterations in hormone metabolism around 
menopause to cause a major influence on growth rate between age 45 and 55.
Recent studies have demonstrated that after a sufficiently long follow-up period, the 
effectiveness of screening of women in their forties is similar to those above age 50.1,5,26,27
However, early studies on the effectiveness of screening in women under age 50 sug-
gested that mortality reductions were small and not statistically significant.4,28,29 Appa-
rently, for younger women it takes longer before trends in mortality between screened 
and unscreened groups diverge. For example, in an evaluation from Sweden the mortality 
reduction in the age-group 40 - 49 was 14% after 10 years29 and 29% after 16 years,27 
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while the mortality reduction in the age group 50 - 69 was already 20% after 10 years 
of follow-up.30 Some have argued that younger patients live longer with breast cancer 
than older patients.31 A long delay before any reduction in breast cancer mortality due to 
screening in younger women becomes apparent is therefore plausible. 
In conclusion, we report that age is not associated with growth rate in ductal breast 
cancer patients aged 50 - 75. However, we suggest that future studies should address the 
issues noted in this study on growth rate in patients under age 50 and in other histologi-
cal subtypes of breast cancer. 
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Currently, there is an extensive and continuing debate on the relevancy of breast cancer 
screening.1,2 In the summer of 2011, Jørgenson3 in his letter entitled “Flawed methods 
explain the effect of mammography screening in Nijmegen” strongly criticised observatio-
nal designs used to evaluate service screening and questioned the extent of the reduction 
of breast cancer mortality.
Another indicator of the actuality of this debate is that after half a century of screening 
experience and practice, the British Medical Journal of December 2010 published a letter 
recommending a new mega-randomised trial.4 This proposal is practically and methodo-
logically a non-issue, because there are other valid methods to acquire unbiased evidence. 
It is even unethical, because a large proportion of women who currently have access to 
screening would then be withheld from any mammographic screening examination.
Service screening can correctly be evaluated by conducting a cohort or a case-referent 
study. A perceived issue with these non-experimental or so called observational studies, is 
the risk that the screening groups to be contrasted may not be comparable, which yields 
the potential of confounding and selection bias.5 Therefore, it is a challenge to correctly 
design an observational study avoiding these issues.6 
The impact of early breast cancer detection on mortality
The first evaluations of breast cancer screening to use an observational design were 
demonstration projects conducted in the early 1980s in Utrecht and Nijmegen.7,8 In 
1984, Professor Frits de Waard9 at the University of Utrecht and the initiator of the breast 
cancer screening project in Utrecht, reacted very enthusiastically to the simultaneous 
publications of these study results in the Lancet. He argued in the Dutch newspaper De 
Volkskrant,10 “Anyone who still dies of breast cancer nowadays has not been systematically 
screened.” Although the studies had wide confidence intervals, their point estimates 
of the effect of screening were very encouraging. The case-control study from Utrecht 
reported a 70% decrease in breast cancer mortality due to screening (odds ratio (OR) = 
0.30; 95% confidence interval (CI) = 0.13 - 0.70) and the Nijmegen study presented a 51% 
mortality reduction (OR = 0.49; 95% CI = 0.23 - 1.00). 
These early case-control studies were designed to measure the efficacy of screening. 
Their results contributed to the launch of the Dutch national screening programme in 
1989. Later on, the promising results from Utrecht and Nijmegen were confirmed by a 
decrease in breast cancer mortality in the Netherlands soon after the start of the nation-
wide programme: the mortality decreased by 28% between 1988 and 2007.11 
Despite these positive results, the estimation of the magnitude of the mortality reduc-
tion due to modern service screening is still somewhat imprecise. The above mentioned 
mortality figures were based on the evaluation of trends. However, with this kind of 
assessment it remains unclear to what extent screening and early treatment have really 
prevented breast cancer deaths. To quantify the preventive effect of screening it is neces-
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sary to make a direct link between a woman’s cause of death and her screening history. 
Therefore, we designed a case-referent study within the long running programme in 
Nijmegen. Our findings have demonstrated that a substantial proportion (65%) of breast 
cancer deaths are prevented by screening and that since the start of screening in Nijme-
gen, now more than 35 years ago, the effectiveness has increased impressively over time.12 
We have even found conclusive results for a mortality reduction in women screened under 
the age of 50.13 
Critical assessment
Notwithstanding the encouraging results from our case-referent study, articles that 
used this design are still being rejected by journals with arguments from reviewers like 
“We have little idea whether results from case-control studies in the screening context 
reflect reality or the numerous data handling, statistical tricks and adjustments” or “The 
question you address is important and topical but I did not feel this study would “end the 
debate” because studies with randomised designs will likely generate much more robust 
and unbiased estimates of effect than case-control or cohort studies such as this one”. 
The idea behind such argumentation is the widespread belief that estimates of screening 
effects from case-referent studies are highly vulnerable to confounding and selection bias 
and therefore invalidated by these biases. 
Confounding bias
In our case-referent study, we estimated the screening effect by approaching the compari-
son outcome of breast cancer mortality in screened and unscreened women by calcula-
ting odds ratios. Confounding bias occurs when the prevalence of a risk factor (or set of 
risk factors) for breast cancer death is different for the screened and unscreened women. 
To adjust for the confounding effect, the prevalence of these factor(s) has to become simi-
lar in both groups. This can be done either by matching or by data-analytical adjustment. 
Usually age is the only risk factor taken into account when evaluating service screening 
programmes. Therefore, beyond the adjustment for age, so called residual confounding 
bias in the screening - mortality relation remains the major criticism. In this regard, 
self-selection bias can be viewed upon as a special form of residual confounding because 
participation may induce an imbalance in risk factors for breast cancer death between 
screened and unscreened women. 
One other candidate that may induce confounding bias in the effect estimate is mam-
mographic density, i.e. the amount of glandular tissue and stroma on the mammogram, 
which in itself is an important risk factor for breast cancer.14 Because this factor is highly 
correlated with age,15 adjustment for age already implies indirect adjustment for mam-
mographic density. Within a representative sample of 2595 women from the screening 
programme in Nijmegen in whom we measured mammographic density, we conducted 
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a case-referent study (data not published). A total number of 95 cases of breast cancer 
death were identified and 475 referents were sampled. The age-adjusted OR between 
breast cancer death and screening was 0.33 (95% CI = 0.21 - 0.54), and similar to the OR 
= 0.33 (95% CI = 0.19 - 0.54) when adjusted for mammographic density. 
Other risk factors for breast cancer like postmenopausal obesity, high socio-economic 
status, nulliparity, late age at menopause, early age at menarche, and family history of 
breast cancer reveal a 1.5 to 4-fold relative risk at the most.16 Using sensitivity analysis,17 
we developed realistic scenarios of the prevalence and strength of these risk factors on 
screened and unscreened groups, and explored the impact of residual confounding bias. 
Our results demonstrated that, having addressed the influence of age, residual confoun-
ding is a minor issue in case-referent studies on screening effectiveness.18 
Selection bias
Another criticism of case-referent studies is the potential of selection bias. This has to do 
with the way the reference group is sampled. For example, in the classical case-control 
approach it was common to compare the screening history of cases of breast cancer 
death with that of a control group which was sampled from the population of women who 
were still alive at the end of the data collection. By this way of sampling, the control group 
will by definition have had more opportunities to participate in screening. Because of this 
possible overrepresentation of screened controls versus unscreened controls, screening 
may virtually appear to be more effective than it in fact is. But, there will be no bias if, as 
in our study, the reference group refers to the probability of having been screened in the 
population from which the cases originate. This means that referents should have had the 
same screening invitation(s) schedule and should have had, at that time, a similar risk of 
dying from breast cancer as the corresponding cases.19,20 In summary, well designed case-
referent studies provide unbiased and valid estimates of the impact of service screening 
programmes.21
Evidence of age-specific effectiveness
With this critical appraisal in mind regarding the results of our case-referent study, we 
conclude that current screening in the Netherlands is a highly effective health care ser-
vice. This means that screening compared to symptomatic detection, discovers a larger 
number of tumours before their fatal diameter occurs.22 Theoretically, each tumour has a 
size at which the cancer becomes fatal, i.e., (micro) metastases have spread and the avai-
lable treatment options are no longer curative. A patient can only be cured if the tumour 
is treated before it has reached this fatal diameter.22 
The assumption that tumours in younger patients tend to grow more rapidly, thereby 
reaching their fatal diameter more quickly, than tumours among older patients, was an 
important explanation for the disappointing effects of screening under age 50 reported 
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by the early studies.23,24 In addition, the unfavourable outcomes for this age group were 
explained by the large numbers of missed tumours at the screening examination due to 
the high breast density prevailing in younger women.
However, recent studies, including ours, have demonstrated that after a sufficiently 
long-term follow-up period, the effectiveness of screening of women in their forties is 
similar to that above age 50.13,25-27 Therefore, the assumption that breast cancer at younger 
age grows faster than at older age may not be valid. This finding prompted us to investi-
gate the association between age at diagnosis and breast cancer growth rate.
Contrary to general belief, our results showed that age is not related to breast cancer 
growth rate. Thus, basically, in women under and over age 50 a similar proportion of 
tumours is likely to be detected before their fatal diameter, and this indicates an equal 
screening effect in both age groups. Apparently, for younger women it takes longer before 
trends in mortality between screened and unscreened groups diverge. For example, in an 
evaluation from Sweden the mortality reduction in the age-group 40 - 49 was 14% after 10 
years24 and 29% after 16 years,26 while the mortality reduction in the age group 50 - 69 was 
already 20% after 10 years of follow-up.28 Some have argued that younger patients live lon-
ger with breast cancer than older patients.29 A delay before any reduction in breast cancer 
mortality due to screening in younger women becomes apparent is therefore plausible. 
Further decline in breast cancer mortality
This finding that there is no association between age and growth rate may have bearing 
on the extension of the screening programme’s age limits in order to reduce breast can-
cer mortality in the total population even further, see Figure 4.1. 
Figure 4.1  Age standardised (European standard population) breast cancer mortality in the Neth-
erlands between 1969 and 2009 (source: Statistics Netherlands).
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Currently in the Netherlands, there are more than 8 million women, of whom 3180 
died from breast cancer in 2010.30 The prospects for reducing the number of deaths by 
screening depends on age limits, numbers of women who are actually screened, the 
sensitivity of the screening test, and the frequency with which women are screened. 
However, maximising the mortality reduction of screening does not guarantee an optimal 
balance of benefit to harm. One of the important side-effects of screening is false positive 
referral, which results in unnecessary diagnostics and unnecessary psychological stress. 
The trade-off between benefits and harms should be taken into account when discussing 
efforts to further reduce breast cancer mortality by screening.31
Age limits 
To optimise the impact of screening, the current age limit for invitation in the Dutch 
screening programme needs to be lowered. We have estimated that halving breast cancer 
mortality can be achieved by screening women in their forties. These results alone do 
not justify starting screening at age 40. Additional evidence on the harms of screening 
women in their early forties will have to be considered when making decisions on com-
mencing screening at 40. However, our results, combined with the fact that breast cancer 
incidence in the Netherlands has increased strongly between the ages of 45 and 49, 
means that starting biennial screening at age 45 can effectively contribute to a reduction 
of the burden of breast cancer.32 
On the other hand, mammography is less accurate in younger women.33 As a conse-
quence, the balance between benefits and harms may be less favourable in the age group 
45 - 49 than among those aged 50 and older. Screening performance in the 45 - 49 age 
group will improve when the number of true positive referrals increases while the number 
of false positive referrals remains constant or decreases.34 This may be achieved through 
additional training of radiologists when reading mammograms in younger women. In 
addition, now digital mammography has been implemented in the Dutch screening 
programme, this may offer a better balance between true and false positive referrals 
for women under 50 perhaps together with computer-aided detection.35 Future studies 
should address whether digital mammography can optimise the effect of screening while 
minimising the harms.
In addition to lowering the starting age, continued screening for the elderly may also 
reduce breast cancer mortality.36,37 About 3.3% of this population develops breast cancer 
between age 75 and 85.38 We have demonstrated that these incident cases sustain a 30% 
risk of dying from this malignancy. These findings emphasise the importance of the health 
problem in elderly women and the relevance of screening them.39 However, at old age, 
individual characteristics such as multi-morbidity and deteriorating functional status 
may strongly influence the likelihood of occurring benefits and harms from screening. 
Therefore, screening women over age 75 may especially be relevant for individuals with a 
favourable life expectancy.40 To solve this, a system of self-referral to screening could be 
introduced.41 This system is practised in the United Kingdom, where women can continue 
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to be screened after reaching the upper age limit by requesting an individual screening 
examination.42 We expect that in this system, healthy women who may benefit from early 
breast cancer detection will actively choose to continue participation in screening. 
Mammographic test sensitivity
Although screening substantially reduces breast cancer mortality, the mammographic 
screening test to detect asymptomatic breast cancer is an imperfect means of early 
detection. Not every breast cancer is detected earlier and not every death is prevented, 
even among women who dedicatedly participate in screening. This imperfection of mam-
mographic screening is partly caused by its moderate test sensitivity. In the Netherlands, 
the current sensitivity of mammographic screening is around 70%.11 One main reason for 
this, to a certain extent disappointing sensitivity, is the reduced ability of mammography 
to detect invasive lobular carcinoma. It has been reported that the false negative mam-
mography rates are up to 19% more detrimental in invasive lobular carcinoma compared 
to invasive ductal carcinoma.43 Invasive lobular carcinoma is the second most common 
histological type of breast cancer and it occurs in about 15% of the patients as shown in 
the incidence rates in Figure 4.2. On a mammogram, and in particular on the mediolateral 
oblique views, invasive lobular carcinomas are usually difficult to identify. In subsequent 
screening examinations in the Dutch screening programme a mediolateral oblique view 
is standard, whereas a craniocaudal view is only performed on indication. In most cases, 
however, signs of invasive lobular carcinoma are better visible on craniocaudal views.44 
Now digital mammography has recently been implemented in the Netherlands, it 
makes computer-aided detection relatively more easy to apply. In programmes that have 
Figure 4.2  Breast cancer incidence in the Netherlands in 2009, according to invasive ductal 
carcinoma (IDC), invasive lobular carcinoma (ILC) and ductal carcinoma in situ (DCIS) (source: 
Comprehensive Cancer Centre Netherlands).
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applied this technique for some time, a promising mammographic sensitivity of more 
than 90% for detecting both invasive lobular and invasive ductal breast cancer at an early 
stage have been reported.45,46 The application of computer aided detection in the Dutch 
service screening programme will probably increase referral rates,47 however the incre-
ase in the number of false-positive referrals will probably not outweigh the benefit of the 
increase in the number of true-positive referrals.48 We expect that routine use of two-view 
digital mammography and computer-aided detection systems will contribute to further 
reduction in breast cancer mortality.
Screening interval
In an effort to further reduce breast cancer mortality, one may also think of increasing 
the frequency of screening examinations. The Cancer Intervention and Surveillance 
Modelling Network (CISNET) worked out, using six independent statistical models, that 
annual screening intervals would achieve on average a 20% larger mortality reduction 
than biennial screening shedules.49 Unfortunately, the number of false positive referrals 
will be twice as high in an annual interval compared with a biennial interval. Changing 
the screening programme from biennial to annual would require doubling the capacity of 
service screening to meet this increase. Thus, we recommend that we maintain a biennial 
screening interval.
Stop the debate 
Given these arguments there is a potential for a further reduction in breast cancer morta-
lity. In my recommendation to extend the age range of screening invitation to women in 
their forties and after age 75, I advocate more screening rather than less, while ensuring 
an optimal balance of benefits and harms. That, while the debate on the relevancy of 
screening seems to be the focus of negative discussions, as shown in the extraordinary 
high attention paid to recent papers claiming minor effects of screening, and ignoring five 
decades of research.50 Our results, that mammographic screening currently substantially 
reduces breast cancer mortality seem clear cut. However, the most recent criticism on 
the benefits of screening concerning the methodology and outcomes of my case-referent 
study3 obviously demonstrate that there is still work to be done. 
As we move forward, we must remember that this debate will not be resolved in the 
near future. Different views on the methodology in screening research will maintain 
this debate.51 One view is that of researchers who emphasise evidence and who see 
the randomised trial as the ultimate means to achieve this. However, as I describe in 
the second paragraph of this chapter, a new trial is methodologically a non-issue and 
unethical. The other view is that of researchers who set up studies to evaluate whether a 
patient’s prognosis has improved by screening, and who have developed observational 
study designs to investigate this. These to some extent opposing opinions, give rise to 
discussions. 
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My personal opinion is that after five decades of experience and evidence it is not relevant 
to re-open the discussion on the validity of service screening. It has become an esta-
blished health care service in many countries, and I think it is time that researchers and 
medical personnel involved in screening focus on improving and expanding this valuable 
service. We should close the debate on screening benefits, and start the discussing on 
optimising the impact of breast cancer service screening.
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Currently, there is an extensive and continuing debate on the relevancy of breast cancer 
screening, even though large-scale population based screening programmes have been 
in existence for at least two decades. In particular the extent of the reduction in breast 
cancer mortality as the main benefit of screening has been questioned. 
In contrast to this debate, ongoing discussions on optimising screening program-
mes concern, amongst others, extending the age range of the target population to be 
invited for screening. The results of our research provide evidence for the current impact 
of service screening and support decision-making related to extending the age range of 
screening invitation. 
Impact of screening
Favourable outcomes of randomised trials and demonstration projects in the 1970s and 
1980s demonstrated the efficacy of mammographic screening on breast cancer mortality. 
Since that time, great advances in the organisation of screening and the detection and tre-
atment of breast cancer have been made, which are expected to result in the continuation 
of these favourable effects or an even greater benefit due to screening over time. 
We demonstrated that mammographic screening has become more effective across 
the period 1975 - 2008, resulting in a 65% breast cancer mortality reduction in 1992 - 
2008 compared with a 28% reduction in 1975 - 1991. Our findings provide evidence that, 
currently, breast cancer service screening is a highly effective health care facility. This 
while the debate on the screening benefits is being fuelled by claims that the reduction in 
breast cancer mortality due to screening is only minor.
Our results stem from a case-referent study. A perceived issue with this non-expe-
rimental or observational design is the risk that the screening groups to be contrasted 
may not be comparable, which yields the potential of confounding and selection bias. 
Having accounted for age, the major criticism of observational studies on breast cancer 
screening effectiveness is residual confounding bias. We developed realistic scenarios for 
the prevalence and strength of other risk factors for breast cancer death in screened and 
unscreened groups. The results demonstrate that residual confounding is a minor issue 
in estimates of breast cancer screening effectiveness. 
Although screening substantially reduces breast cancer mortality, not every breast 
cancer death is avoided by early detection. This imperfection of mammographic screening 
is partly caused by its moderate test sensitivity. In the Netherlands, the current sensitivity 
is around 70%. One main reason for this, to a certain extent disappointing sensitivity is 
the reduced ability of mammography to detect invasive lobular carcinoma (10 - 15% of 
the patients). We have shown that screening did not help to prevent death in patients 
diagnosed with invasive lobular carcinoma. However, we expect that new mammographic 
screening techniques, such as digital mammography and computer aided detection, will 
contribute to the early detection of lobular carcinoma. 
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Age targets
Screening younger women
Most service screening programmes, including the Dutch one, start to invite women from 
age 50. We show that there is a gradual change, if any, in screening outcomes and breast 
cancer incidence along the continuum of age. These findings indicate that it is fairly 
arbitrary to commence screening at age 50. In the Netherlands, the current breast cancer 
incidence at age 45 - 49 is similar to the incidence registered in women aged 50 - 59 at the 
start of the national screening programme two decades ago. This observation underpins 
a reconsideration of the starting age in breast cancer screening to age 45.
In an observational study using data from the Nijmegen screening programme, we 
identified all breast cancer deaths in women invited for screening between age 40 and 69 
and compared their screening history with that of a reference population. We found that 
among women aged 40 - 49 mammographic screening may halve the risk of dying from 
breast cancer. 
Screening the elderly
Women older than 75 are not invited to organised breast cancer screening programmes. 
The major argument against inviting this age group is that these women have a short life 
expectancy and are more likely to have multi-morbidity than younger women. Therefore, 
even if elderly women are diagnosed with breast cancer, they might be expected to die of 
other causes. We estimated that in this age group 3.3% of the women will be diagnosed 
with breast cancer, and that these incident cases sustain a 30% risk of dying from breast 
cancer within 10 years after diagnosis. These findings emphasise the importance of the 
health problem caused by breast cancer in elderly women and the relevance of reconside-
ring screening this age group. 
Age and breast cancer growth rate 
A meta-analysis of the randomised screening trials demonstrated a small mortality 
reduction in women aged 50 - 59 and a large effect in the age group 60 - 69. A possible 
explanation for this difference is the assumption that tumours among younger patients 
tend to grow faster than tumours among older patients. We, therefore, investigated the 
association between age at diagnosis and breast cancer growth rate, using longitudinal 
series of screening and diagnostic mammograms. 
Contrary to the general belief, our results show that age is not related with breast can-
cer growth rate. Thus, basically, in women under and over age 60 a similar proportion of 
early stage cancers is likely to be detected. This supports, unlike the results of the meta-
analysis, an equal screening effect in both age groups. 
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Concluding remarks
In this thesis, I give evidence for starting biennial breast cancer screening at age 45 and 
evidence for continuation of screening after age 75. In my recommendation to extend the 
scope of screening, I advocate more screening rather than less. That, while there is still an 
extensive debate on the benefits of screening. My results demonstrate that the reduction 
in breast cancer mortality risk for women currently participating in screening is impres-
sive, thereby clearly confirming the benefits of modern service screening. 
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Screening naar borstkanker beoogt deze ziekte tijdig te ontdekken, waardoor de kans op 
genezing toeneemt. Begin jaren negentig is in diverse westerse landen gestart met groot-
schalig bevolkingsonderzoek naar borstkanker. Hoewel de uitvoering van de screening in 
die landen verschillend georganiseerd is, richten de meeste bevolkingsonderzoeken zich 
op vrouwen in de leeftijd van 50 tot 70 of 75 jaar. Nederland screent van 50 tot 75 jaar.
Na ruim twee decennia praktijkervaring met het bevolkingsonderzoek, wordt momen-
teel in de wetenschappelijke literatuur hernieuwd een stevig debat gevoerd over de mate 
waarin screening de borstkankersterfte reduceert. Sommige onderzoekers beweren zelfs 
dat het bevolkingsonderzoek naar borstkanker zinloos is. Terwijl een deel van de onder-
zoekers twijfelt aan het nut van het bevolkingsonderzoek, discussiëren anderen over 
optimalisering en verbreding van de screening om de sterfte aan borstkanker verder te 
verminderen. Een veel bespoken optie is de uitbreiding van de leeftijdsgroepen. De kans 
op borstkanker neemt al vóór het vijftigste levensjaar sterk toe, namelijk vanaf 40 jaar. 
Om die reden wordt de vraag gesteld of vrouwen van 40 - 49 jaar niet in aanmerking 
zouden moeten komen voor bevolkingsonderzoek. Daarnaast zou screening bij vrouwen 
ouder dan 75 jaar ook gezondheidswinst kunnen opleveren. De laatste decennia is de 
levensverwachting immers sterk toegenomen en vormen 75-plussers in Nederland een 
grote en snel groeiende bevolkingsgroep.
De resultaten van dit proefschrift leveren bewijs over het hedendaagse gunstige effect 
van screening op de borstkankersterfte en ondersteunen beslissingen over de uitbreiding 
van de leeftijdsgroepen.   
Hedendaags effect van screening op de borstkankersterfte
In de jaren zestig en zeventig werden diverse gerandomiseerde studies en demonstratie-
projecten opgezet om het effect van mammografische screening op de borstkankersterfte 
te onderzoeken. In Nijmegen ging in 1975 een proefbevolkingsonderzoek van start. Uit de 
evaluatie van dit Nijmeegse programma en van andere studies kwam een gunstig effect 
op de sterfte naar voren. Hierna zijn diverse westerse landen overgegaan tot periodiek 
mammografisch bevolkingsonderzoek. 
De afgelopen decennia zijn de mogelijkheden tot vroege opsporing alsmede de 
behandeling van borstkanker aanzienlijk verbeterd. Wij stelden ons daarom de vraag of 
deze veranderingen van invloed zijn geweest op de effectiviteit van mammografische 
screening. We waren in staat dit over een periode van ruim dertig jaar te onderzoeken 
door gebruik te maken van uitvoerige gegevens van één van de langst lopende bevolkings-
onderzoeken naar borstkanker ter wereld, te weten het Nijmeegse programma. Uit onze 
studie blijkt dat het effect van screening erg groot is en dat dit in de loop der jaren alleen 
maar verder is toegenomen. Daar waar in de jaren 1975 - 1991 de borstkankersterfte onder 
gescreende vrouwen 28% lager lag dan de sterfte onder niet-gescreende vrouwen, is de 
sterfte tegenwoordig zelfs 65% lager. Deze resultaten laten zien dat het bevolkingsonder-
zoek een zeer zinvolle gezondheidszorgvoorziening is. 
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Voor onze studie hebben wij een case-referent design gebruikt, in het Nederlands ook wel 
bekend als een patiënt-controleonderzoek. In dit onderzoek werd de deelname aan het 
bevolkingsonderzoek bij vrouwen die aan borstkanker zijn overleden vergeleken met de 
deelname in een controlegroep van uitgenodigde vrouwen. Bij een dergelijk onderzoeks-
ontwerp kan het zijn dat de te vergelijken groepen van gescreende en niet-gescreende 
vrouwen verschillend zijn wat betreft risicofactoren voor borstkankersterfte. Als dat het 
geval is, kan dit resulteren in een niet precieze of onjuiste schatting van het effect van 
screening op borstkankersterfte. Er is dan sprake van verstoring van het effect, of te wel 
confounding bias. 
Zowel bij de opzet als de analyse van een case-referent studie valt eenvoudig reke-
ning te houden met de potentiële confounding van de belangrijke risicofactor leeftijd. 
Behoudens leeftijd kan er nog steeds sprake zijn van verschillen tussen de te vergelijken 
groepen wat betreft andere risicofactoren voor sterfte aan borstkanker. Deze zogenoemde 
residuele confounding bias is een veel gehoord kritiekpunt op het gebruik van case-refe-
rent studies binnen de evaluatie van bevolkingsonderzoek naar borstkanker. 
Wij hebben onderzocht in welke mate residuele confouding invloed kan hebben op het 
screeningseffect. Onze resultaten tonen aan dat de residuele confounding hoogstens een 
klein effect heeft op de uitkomst van de case-referent studies. Het case-referent design is 
derhalve een geschikte en valide onderzoeksmethode voor de evaluatie van het bevol-
kingsonderzoek.
Hoewel onder gescreende vrouwen de borstkankersterfte aanzienlijk lager ligt dan 
onder niet-gescreende vrouwen, voorkomt screening niet alle borstkankersterfte. Dit 
wordt deels verklaard door de niet volmaakte sensitiviteit van de screeningsmammo-
grafie. Tegenwoordig heeft het Nederlandse bevolkingsonderzoek een sensitiviteit van 
70%. Deze sensitiviteit wordt onder andere veroorzaakt door de moeizame detectie van 
het invasief lobulair carcinoom. Het invasief lobulair carcinoom komt in 10 - 15% van de 
borstkankerpatiënten voor. Wij vinden geen bewijs voor een reductie van de sterfte aan 
lobulair carcinoom bij gescreende vrouwen. Nieuwe screeningstechnieken, zoals het 
standaard toepassen van craniocaudale opname naast de mediolaterale oblique opname, 
digitaal screenen en computer-ondersteunende detectie, zullen naar verwachting gaan 
bijdragen aan doeltreffende vroege detectie van het lobulair carcinoom.   
Leeftijdsgroepen
Screening bij jonge vrouwen
In de meeste landen met bevolkingsonderzoek naar borstkanker, waaronder Nederland, 
worden vrouwen voor het eerst uitgenodigd op 50 jarige leeftijd. In tegenstelling tot de 
positieve effecten bij de 50-plussers zijn in het verleden geen overtuigende onderzoeks-
resultaten gevonden voor een gunstig effect van screening bij vrouwen van 40 - 49 jaar. 
Aan de andere kant is er geen sterk bewijs dat 50 jaar de optimale startleeftijd is voor het 
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bevolkingsonderzoek. De effectiviteit van screening zal logischer wijs niet ineens wezen-
lijk verschillen voor vrouwen net boven of onder de 50. 
Bij jongere vrouwen, met name tussen de 45 en 49 jaar, komt borstkanker steeds vaker 
voor. Wij hebben daarom ook een case-referent onderzoek uitgevoerd naar het effect van 
screening bij vrouwen onder de 50 jaar. Onze resultaten tonen aan dat screening bij deze 
leeftijdgroep de sterfte aan borstkanker kan halveren. Een verlaging van de startleeftijd 
naar 45 jaar lijkt dan ook een goede mogelijkheid om de borstkankersterfte in Nederland 
verder te reduceren.
Bij deze verlaging van de startleeftijd dient te worden gezocht naar een optimale 
balans tussen de voor- en nadelen van het bevolkingsonderzoek. Mammografie is minder 
nauwkeurig in het vroegtijdig opsporen van borstkanker bij jongere vrouwen. Als gevolg 
hiervan kan de balans tussen voor- en nadelen bij deze jongste leeftijdsgroep minder 
gunstig uitvallen dan bij 50-plussers. Training van radiologen, digitale mammografie 
en computer-ondersteunende detectie, zullen naar verwachting gaan bijdragen aan een 
optimale balans tussen voor- en nadelen van het bevolkingsonderzoek bij vrouwen in de 
leeftijd 45 - 49.
Screening bij oudere vrouwen
De bovenste leeftijdsgrens van het Nederlandse bevolkingsonderzoek naar borstkanker 
ligt op 75 jaar. Screening bij vrouwen ouder dan 75 jaar wordt niet zinvol geacht vanwege 
de beperkte levensverwachting en de toenemende aanwezigheid van andere ziekten 
of aandoeningen. Concurrerende ziekte- en sterfteoorzaken zouden het voordeel van 
screening teniet doen. Daarentegen komt borstkanker op hoge leeftijd veel voor. Uit 
ons onderzoek blijkt dat 30% van de vrouwen die na hun 75ste met borstkanker worden 
geconfronteerd, alsnog aan deze ziekte komt te overlijden. Deze resultaten pleiten ervoor 
75-plussers de mogelijkheid te geven, deel te blijven nemen aan het bevolkingsonder-
zoek. Een elegante oplossing hiervoor zou het Britse systeem van ‘self-referral’ kunnen 
zijn. Dit stelt oudere vrouwen in staat om op eigen initiatief een afspraak te maken voor 
screeningsonderzoek binnen de setting van het bevolkingsonderzoek.   
Leeftijd en groeisnelheid van borstkanker 
Een ander veelgehoord argument tegen verhoging van de leeftijdgrens bij het bevolkings-
onderzoek, is dat borstkanker bij oudere vrouwen veel langzamer zou groeien. Vroege 
ontdekking zou niet nodig zijn voor een effectieve behandeling. In onze studie bereken-
den we bij patiënten in de leeftijd 50 - 75 met invasief ductaal carcinomen de groeisnel-
heid aan de hand van opeenvolgende screeningsmammogrammen. In tegenstelling tot 
de aanname dat de groeisnelheid bij oudere vrouwen zou afnemen, tonen wij aan dat er 
geen enkel verband bestaat tussen leeftijd en de groeisnelheid van borstkanker.
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Tot slot
In dit proefschrift draag ik bewijs aan voor zowel verlaging als verhoging van de leeftijds-
grens bij het bevolkingsonderzoek naar borstkanker. In deze aanbeveling voor uitbreiding 
van de leeftijdsgrenzen bepleit ik juist meer screening in plaats van minder; dat terwijl er 
uitvoerig wordt gediscussieerd over en getwijfeld aan de voordelen van het bevolkings-
onderzoek. In mijn advies wil ik benadrukken dat bij uitbreiding van de doelgroep gezocht 
moet worden naar de optimale balans tussen de voor- en nadelen van het bevolkings-
onderzoek. Mijn resultaten tonen aan dat borstkankerscreening tegenwoordig een zeer 
effectieve gezondheidszorgvoorziening is, die borstkankersterfte in sterke mate reduceert.
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Dit proefschrift is af! Ik ben erg blij met het resultaat, en kijk terug op de mooie tijd die 
dit promotietraject voor mij is geweest. Een periode waarin ik me heb toegelegd op het 
verrichten van wetenschappelijk onderzoek naar de effectiviteit van borstkankerscreening 
en me heb verdiept in de epidemiologie. Maar ook een periode waarin ik ben getrouwd en 
vader ben geworden van twee lieve jongens. Ik heb met veel plezier gewerkt en met een 
groep fijne mensen samengewerkt. Ik wil iedereen dan ook hartelijk bedanken die heeft 
bijgedragen aan de totstandkoming van dit proefschrift. 
 
Beste André, mijn promotor. Natuurlijk hoor jij, volgens de ‘proefschrift etiquette’, op 
deze eerste plaats in het dankwoord te staan. Maar ik zou ook niet anders willen. Je was 
voor mij een geweldig fijne promotor. Bij alle projecten was je vanaf het eerste begin 
stimulerend en erg betrokken. Je hebt originele ideeën, maar je kunt ook pragmatisch zijn 
en me bijvoorbeeld stimuleren tot afronding van een artikel. Je hebt me als onderzoeker 
en als mens veel geleerd en laten groeien. Groeien in het doen van onderzoek en in de 
epidemiologie. Je stond aan de basis van dit promotie traject, maar dacht ook met me 
mee over mijn verdere ontwikkeling en mijn carrière. Je introduceerde me bij de Sociale 
Geneeskunde, waar ik in mijn nieuwe baan mijn affiniteit met de Public Health verder kan 
uitdragen. Bedankt!
Beste Mireille, mijn copromotor. Ik wil je hartelijk bedanken voor je prettige begeleiding 
en waardevolle inbreng. Je belichtte zaken vanuit een ander kader en had een wezen-
lijke rol bij het succesvol schrijven van de hoofdstukken in dit proefschrift. Je was altijd 
gedreven en enthousiast. Naast je inhoudelijk inbreng waardeer ik je ‘internationale  blik’ 
en het belang dat je hecht aan het onderhouden van netwerken. Zo heb je me in contact 
gebracht met Sue Moss, een epidemiologe aan the Institute of Cancer Research in Lon-
den, bij wie ik een aantal weken heb gewerkt. Ik heb veel bewondering voor je werklust en 
voor je efficiënte manier van werken. 
 
Beste Ard, mijn promotor. Jouw praktijkervaring was waardevol voor mijn onderzoek. Je 
stond altijd dicht bij de (inter)nationale beleidsontwikkelingen omtrent het bevolkingson-
derzoek naar borstkanker. Als er nieuwe spannende artikelen over borstkankerscreening 
in tijdschriften verschenen, stuurde je die meteen naar mij en de andere Boca-spelers 
door. Je hebt mij geënthousiasmeerd voor het prikkelende debat in de wetenschappelijke 
literatuur rondom de borstkankerscreening. Hartelijk bedankt voor de zeer plezierige 
samenwerking.
Beste Roland, ik heb je leren kennen als iemand met grote interesse in mijn onderzoek. Je 
was op afstand kritisch betrokken bij mijn werk. Hartelijk dank hiervoor. 
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De leden van de manuscriptcommissie, Toine Lagro-Janssen, Nico Karssemeijer en Harry 
de Koning, bedankt voor de inhoudelijke beoordeling van mijn manuscript. 
Mijn paranimfen, Ellen en Hans, fijn dat jullie 2 februari naast me staan. Ellen, wij zijn 
ons promotie onderzoek naar borstkankerscreening tegelijk gestart en ronden het nu 
vrijwel gelijktijdig af. We zaten en zitten dus in ‘het zelfde schuitje’. We deelden een 
kamer en hebben daar veel zin en onzin besproken. We hebben ons vast gebeten op het 
case-referent design, gingen samen op congres en deelden frustraties en vreugde over het 
doen van onderzoek. Ik vond het erg prettig en gezellig om met je op te trekken en zal het 
samenwerken missen. Je was een geweldige collega en kamergenoot. 
Hans, het was buitengewoon fijn om zo’n doorgewinterde collega te hebben. Toen ik dit 
promotietraject startte, moest ik me het doen van onderzoek, het veld van borstkanker-
screening en de epidemiologie eigen maken. Jij bent de man bij uitstek die ‘the ins and 
outs’ kent van de Nijmeegse screeningsdata. Jij was altijd bereid om te helpen, mee te 
denken en kwam met goede ideeën. Jouw betrokkenheid gaat verder dan het werk alleen. 
Met tips over huizen, auto’s, de heg snoeien en het schilderwerk van de buitenboel. Ook 
nu ik niet meer op jullie afdeling werk, zoeken we elkaar op om in de pauze te wandelen 
en bij te kletsen. 
Samen met Ellen en Hans werkte ik in het Boca team. Ik heb nooit helemaal begrepen 
hoe we tot een dergelijke naam zijn gekomen. Boca is namelijk een samenvoeging van de 
begin letters van het Nederlandse ‘Borst’ en het Engelse ‘Cancer’. Misschien deze naam 
omdat we ons richten op het Nederlandse screeningsprogramma maar dit voornamelijk 
publiceren in internationale bladen. Enfin, ik wil bij deze ook de andere Boca-spelers, 
Monique, Janine, Wim en Erik danken voor de plezierige samenwerking. 
Ten eerste Monique. Met jou heb ik honderden mammogrammen bekeken en tumoren 
gemeten voor mijn onderzoek naar groeisnelheid. Daarnaast heb je me geregeld gehol-
pen bij andere projecten. Janine, ondanks het feit dat ons onderzoek weinig raakvlakken 
had, was je een zeer geïnteresseerd en een gezellig Boca-lid. Erik, ik sta nog steeds ver-
steld hoe jij op een indrukwekkende en ambachtelijk manier met MS-Dos werkt en weet 
om te gaan met duizenden gegevens en getallen. Je beheert de data op zeer nauwkeurige 
en efficiënte manier. Ik wil je bedanken voor je onmisbare bijdrage aan mijn proefschrift. 
Wim, je hebt mij het werken met SAS bijgebracht en hebt me enorm geholpen bij data 
analyses en het maken van figuren. Jouw rust, luisterend oor en enthousiasme maakt dat 
je niet alleen een geweldige programmeur bent maar ook een goed docent. 
During my PhD training, I spent two months at the Cancer Screening Evaluation Unit of 
the Institute of Cancer Research (ICR) in London, the United Kingdom. At the ICR,  
I worked, under the supervision of Dr Sue Moss, on the case-referent study design and 
the issue of screening younger women. Sue, thank you very much for your warm welcome, 
and for your instructive and valuable contributions whilst performing my studies.
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I would also like to thank the other researchers at the ICR, Rachel, Roger and Louise. You 
made me feel at home at the ICR and arranged a bicycle for your Dutch colleague! Thank 
you very much for your help, interest and hospitality.
Roger, our teamwork has resulted in reviewers saying ‘the manuscript is written in excel-
lent English and its compact style makes reading it very easy’. Many thanks for your con-
tribution to the papers in my PhD thesis. I told you that I have an interest in the English 
language and am therefore looking forward to meeting you once again in one of your 
advanced English classes. 
Afgelopen zomer was mijn proefschrift grotendeels afgerond en heb ik de overstap 
gemaakt van de afdeling Epidemiologie, Biostatistiek en HTA (EBH) naar mijn nieuwe 
baan bij de afdeling Eerstelijnsgeneeskunde. Ik heb ruim 4 jaar op de afdeling EBH 
gewerkt en heb me daar zeer thuis gevoeld. Ik heb genoten van de gezellige koffie pauzes, 
cake-van-de-week en het halfjaarlijkse bowling-uitje. Collega’s, bedankt voor de fijne 
samenwerking en de gezelligheid. 
Twee van mijn nieuwe collega’s, Koos van der Velden en Ron Hameleers wil ik ook in 
mijn dankwoord noemen. Door de prettige samenwerking kon ik op een fijne manier mijn 
nieuwe baan opstarten en tegelijkertijd mijn proefschrift afronden. Dank hiervoor!
Beste Renée, bedankt voor het maken van het kunstwerk voor de omslag van dit boekje. 
Ik vind het erg mooi geworden. Jouw werk, gemaakt van punaises op doek, krijgt een pro-
minente plaats in ons huis en is een mooie herinnering aan mijn promotieonderzoek.
Beste Lenny, Hans, Monique, Oswald, Cindy, John, Rogier, Peter, Frank en Wim, bedankt 
voor alle vriendschap en gezelligheid afgelopen jaren! Naast alle promotiedrukte zorgde 
onze vriendschap voor de nodige ontspanning. Met ‘de jongens’ eten, spellen doen, naar 
debatten in de Lux en naar Londen. Films kijken op het Rotterdam filmfestival met film-
beschrijvingen als ‘zelfs het gras beweegt niet’. Met de ‘Berlijn-groep’ weekendjes weg, 
sinterklaas, kerstdiner, oud en nieuw, verjaardagen en tegenwoordig ook naar de speeltuin 
met onze kinderen. Ik zie uit naar een toekomst met nog veel meer gezelligheid! 
Chris, Leni, Huub, Maria, Martin en Fleur. Bedankt voor het warme welkom in de familie. 
Leni en Chris, ik heb genoten van onze gesprekken aan de keukentafel en jullie oprechte 
interesse in mijn werk en persoon.
Ria, Maruska en Motje, met jullie heb ik er een geweldig lieve familie bij gekregen! Lieve  
Ria, ik ben heel erg blij dat mijn vader zo ’n fijne partner heeft gevonden.
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Mijn lieve ouders, Pa en Ma, bedankt voor jullie warme opvoeding. Als epidemioloog 
bekijk ik de gezondheid op populatie niveau, maar door de ziekte van mijn moeder heb 
ik ervaren wat borstkanker op persoonlijk vlak teweeg kan brengen. Lieve Mam, helaas is 
deze ziekte jou niet gespaard gebleven en kun je mijn proefschrift nooit lezen. Al kwam 
het onderwerp van dit proefschrift toevallig op mijn pad; ik vind het mooi – zij het symbo-
lisch – op deze ziekte te promoveren. Pap, ik ben trots op jou en op de manier hoe jij mij 
altijd hebt gesteund in mijn ontwikkeling. 
Jaap en Wout, m’n lieve jongens, jullie zijn geboren tijdens mijn promotietijd. Wat is 
het leven mooi met jullie. Jullie tweeën doen mij temeer beseffen dat ‘alles van waarde 
weerloos is’.
Tot slot mijn lieve Janet. Deze laatste alinea van mijn dankwoord is voor jou. Je hebt me 
gesteund om verder te studeren, dit promotietraject ‘aan te gaan’ en mijn ambities te 
verwezenlijken. Het is fijn om samen met jou te zijn. Janet, mijn liefste en mijn maatje, 
ik ben dolgelukkig dat ik met jou het leven mag vieren. Op naar nog veel gelukkige en 
liefdevolle jaren samen!
Guido
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